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Disrupted in Schizophrenia 1 (DISC1) is a candidate risk gene in several major mental 
illnesses, e.g. depression, bipolar disorder, and schizophrenia. The full-length DISC1 protein 
comprises of 854 amino acids. It is a scaffold protein that interacts with a very large number of 
other proteins, forming a sizeable protein-protein-interaction network that coordinates various 
stages of  brain development. One of those important interactors is the enzyme, glycogen synthase 
kinase 3β (GSK3β). As a target for lithium, GSK3β itself is implicated in bipolar disorder. The 
interaction of DISC1 and GSK3β was discovered at the cross-section of the canonical Wnt/β-
catenin signalling which controls the proliferation of neural progenitors. DISC1 specifically 
inhibits GSK3β’s function in this pathway via a direct physical interaction. GSK3β is involved 
with the Axin-APC complex in this pathway, and its main role is to phosphorylate and regulate 
the levels of β-catenin in the cell which in turn is a regulator of gene expression levels. The most 
potent GSK3 inhibitory region has been mapped to a small region in the N-terminus (residue 
195-238) of DISC1. This 44-amino acid region (hD1) inhibits GSK3 in an ATP non-competitive 
mechanism and its binding site partially overlap with that of a peptide from another GSK3β 
binding protein, FRATide. Knowledge regarding the molecular network of the interactions 
between hD1, FRATide, and GSK3β remains elusive. This thesis focusses on the effort towards 
obtaining crystals for the protein complexes GSK3β-hD1 and GSK-hD1-FRATide. Crystals of the 
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1 Chapter 1: Introduction 
1.1 Psychiatric illnesses: DISC1 and its importance in etiology 
 More than 16% of the world population experienced psychiatric illnesses in 20191. 
Schizophrenia, autism spectrum disorder, and depression are some of the mental disorders which 
can severely impact quality of life and pose a significant economic burden. Complex genetic 
factors, variation in the etiology across different groups of the population, and environmental 
effects raise significant challenges in understanding the molecular basis of psychiatric diseases. 
Defects in neurodevelopmental processes have been found to be at the central stage of etiology for 
the aforementioned psychiatric illnesses2. 
Genetic inheritance of schizophrenia and related illnesses was established via twin and 
adoption studies as well as genetic analysis of large pedigrees3. The need to determine genetic 
factors for psychiatric diseases led to an extensive search by the scientists for the different genes 
involved, their mutations, and the study of altered functions. A large Scottish family with a high 
prevalence of a variety of psychiatric illnesses, such as schizophrenia, major depressive disorder, 
and autism, was investigated to uncover the critical genetic factor. Two genes, Disrupted in 
Schizophrenia 1 & 2 (DISC1/2) were discovered to have a balanced translocation (1; 11) (q42; 
q14.3) that co-segregated with major psychiatric illnesses in the family4,5. Multiple SNPs and 
haplotypes of DISC1 have also been linked to segregation of autism spectrum disorders and 
asperger syndrome in Finnish families4. Association of the DISC1 protein with a high incidence 
of multiple neuropsychiatric disorders garnered the interest of researchers to understand its 
structure, function, and interaction.  
Further research using tissue cell culture, animal models, and human brain samples of 
schizophrenic patients provided evidence of DISC1’s biological role in different stages of 
neurodevelopment. “DISCopathies” is a term used to categorize mental disorders resulting from 
the malfunctioned DISC1 protein6. The protein has been found at the convergence of multiple 
critical neuro-developmental pathways. The pathways involved are responsible for a diverse array 
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of functions in the brain such as neural progenitor proliferation, neural plasticity, memory, neural 
migration, and maturation7. The multifunctional nature of DISC1 can be attributed to the structural 
ability of the protein to interact with many different protein partners8.  
1.2 DISC1: Structure, function, and its protein interactome 
A DISC1 interactome was established using a yeast two-hybrid system (Y2H), and it 
identified potential cellular pathways based on the function of the interactors9,10. DISC1 
interactome analysis determined an array of proteins from the human fetus and adult brain libraries 
to potentially interact with DISC1. The research implied a strong involvement of the protein in 
neuronal migration, progenitor proliferation, and NMDA receptor activation (glutamate 
receptors)9. A multi-faceted functional capacity of the protein makes it a distinct and ideal target 
for novel therapeutics aimed at psychiatric illnesses. Novel therapy designing would succeed when 
DISC1 and a specific interacting partner are targeted from a particular pathophysiology. This 
process, however, has a significant hurdle. The three-dimensional atomic model of DISC1 is 
unknown. The availability of a high-resolution molecular structure of DISC1 will give crucial 
insight into its function.  
The lack of structural data for DISC1 impedes our understanding of how mutations and 
SNPs give rise to pathophysiology. Sequence analysis has been used by scientists to understand 
the nature of different regions on DISC1 protein. These findings may provide leads to purify 
specific regions of the protein along with the concerned interacting partner. The DISC1 gene 
contains 13 exons. Many splice variants of the protein exist. The longest version, DISC1-L-
isoform, contains 854 amino acids with a molecular weight of ~100 kDa. Sequence analysis reveals 
two major distinct regions of human DISC1: an N-terminal region (1-350) and a C-terminal region 
(350-854). Sequence alignment and comprehensive bioinformatics studies show more significant 
conservation in the C-terminal region when compared with the N-terminus5,11–13. 
1.2.1 N-terminal disordered region 
Only a few notable conserved regions are recorded in the N-terminus of the protein: nuclear 
localization signal (NLS) and serine-phenylalanine-rich (SF-rich) motifs (Fig 1-1)12,13. The N-
terminal region (1-350 amino acid) of the protein was previously recognized as a globular domain, 
which means it is natively folded5,12. However, an improvement of the sequence analysis algorithm 
that considers both secondary structure and disorder sequence signature concurrently suggests that 
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the N-terminus of DISC1 may be unstructured14,15. Intrinsically disordered proteins carry a distinct 
sequence identity, where the majority of the amino acids are highly charged and hydrophilic. These 
amino acids (e.g. Glu, Asp, Lys, Ser, Pro, Arg, etc.) constitute 60% of the N-terminus in DISC17. 
DISC1 has a ~15% serine and ~23% alanine and glycine content in the N-terminal region12. This 
analysis strongly suggested an intrinsically disordered nature of the N-terminus with very low 
complexity14. Updated sequence analysis revealed a ~65% disordered content in the N-terminus. 
Five intrinsically disordered portions were predicted: (i) 1-35 (ii) 65-95 (iii) 146-205 (iv) 218-260 
(v) 278-322 amino acid residues7 (Fig 1-1). This result gave the first insight into the intrinsic 
disorder of the N-terminus of DISC1. 
A significant percentage (~33%) of the eukaryotic proteome is partially or entirely 
disordered, most of the disordered protein being at the intersection of cellular regulations and 
signalling16. One theory suggests the ability of disordered regions to be involved in a plethora of 
signalling pathways. The disordered regions can transition into more folded structures whenever 
they bind to a protein target. Multiple structural transitions allow the protein to be able to interact 
with many signalling cascades. This could be the reason why DISC1 interactome involves more 
than 200 diverse proteins9. Another theory suggests the availability of a substantial intermolecular 





Figure 1-1. Biophysical characterization of DISC1. Sequence analysis and experimental data 
suggest an N-terminal disordered region (grey, 1-350 residues). Yellow horizontal bars represent 
five major disordered sites. Nuclear localization signal (NLS) and Serine-phenylalanine (SF) rich 
domains are shown in green and blue small vertical bars inside N-terminus. C-terminus (blue 
horizontal, 350-854) is comprised of many α-helices and coiled-coil regions. Pink vertical bars 
represent regular α-helices, green vertical bars show coiled-coil helices, orange bars represent 
regular and coiled-coil helices7. The typical translocation break from the Scottish pedigree is seen 
at position 5974. Mutations marked with stars are common SNPs found in human DISC1. Anti-
parallel α-helices such as UVR-like regions are predicted with red horizontal bars (in C-
terminus)17. Multiple self-association sites, dimerization, and oligomerization sites are highlighted 
with purple bars18. The light brown bars indicate interaction sites for GSK3β, the rectangular 
section (contrary to smooth end bars of the same colour) containing the most potent interacting 
and inhibiting region (hD1)19. Horizontal dark blue colour represents the minimum necessary 
interaction site for NDEL120.  
1.2.2 C-terminal region with self-association and oligomerization sites 
The C-terminus of DISC1 is defined by multiple heptad repeats with a pattern of “abcdefg” 
amino acids where the 4th position is often a non-polar residue. Few of these repeats (helices) get 
intertwined to provide stability via supercoil formation21. DISC1 contains at least four regions with 
the structural potential of a coiled-coil region: residues (i) 347-393, (ii) 452-499, (iii) 603-680, and 
(iv) 805-8287. Coiled-coil regions have been associated with protein-protein interaction surface 
and oligomerization potential which could be the case for DISC1.  Besides these regions, analyses 
by multiple programs suggest at least five α-helical regions in the C-terminus. 
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Analysis of the purified full-length DISC1 protein by dynamic light scattering (DLS) and 
size-exclusion chromatography initially suggested the possible existence of a dimer or a higher-
order structure in mammalian cell lines22. Brandon et al. observed DISC1 with a molecular weight 
of ~250 kDa, suggesting at least a dimerized state combined with other possible oligomeric states. 
Oligomerization of proteins is often determined via self-interacting domains. A self-interacting 
domain (residue 403-504) containing a leucine zipper (455-495) was discovered via deletion 
studies23. Oligomerization is often aided by the presence of a leucine zipper (Fig 1-1). 
 The self-association domain described above is flanked by two UVR domains. The UVR 
domains (found across many species) are capable of self-association while often being part of the 
protein-protein interaction interfaces. They are characterized by anti-parallelly packed α-helices 
connected via a left-handed twist24. The UVR-like regions in DISC1 are predicted to be between 
residues 343-394 and 574-62517.  
 Other sites necessary for the oligomerization states of DISC1 were discovered while the 
NDEL1 (Nuclear distribution element 1)-DISC1 interaction sites were being investigated. A 
DISC1 fragment with residues from 598-854 was observed with the simultaneous presence of 
dimeric, octameric, and oligomeric states, and only the species with the octameric state was able 
to interact with NDEL120. These findings suggest a possible adaptive mechanism of 
oligomerization for specific interactions in the cell. Further analysis of DISC1 segments with 
multiple lengths, provided proof of another coiled-coil region (765-854), while a stretch of residues 
from 668 to 747 was responsible for multimerization of DISC1 (Fig 1-1)18. 
1.2.3 Studying DISC1-protein interaction framework 
The large size of DISC1 and the intrinsic disorder in the N-terminus region are possibly 
the key reasons that impede expression/purification and crystallization of the full-length protein. 
The sequence analysis of disordered regions can be used to design constructs that are more 
ordered25. Another option is to co-express the protein with an interaction partner. Out of more than 




1.3 Discovery of DISC1’s interaction with the protein kinase GSK3β 
Since the discovery of DISC1’s implication in many neurodevelopmental defects, 
researchers have investigated the structure and function of the protein. Mao et al.19 used DISC1 
transgenic mouse lines to characterize its expression and function. High level of DISC1 expression 
was observed in nestin- and Sox2-positive neural progenitors present in the ventricular and 
subventricular zone of the cerebral cortex in the embryo. These zones are actively involved in 
neurogenesis. In the adult mouse brain, DISC1 was found to be highly expressed in the dentate 
gyrus and the olfactory bulbs, both regions that can still undergo neurogenesis. 
Therefore, neural progenitor proliferation became a mechanism of interest where DISC1 
might be actively engaged19. This hypothesis was tested both in vitro (AHP cells) and in utero 
(embryonic mouse brains- E13/14/15). Cell proliferation rates were significantly affected by a  
knockdown of DISC1. Progenitor proliferation halted, and early cell cycle exit was observed in 
the absence of DISC1. This set of experiments strongly suggested that DISC1 plays a decisive role 
in progenitor proliferation and that knockdown of DISC1 potentially leads to premature cell cycle 
exit and differentiation.  
 Wnt/β-catenin canonical signalling plays a significant role in regulating progenitor 
proliferation in the nervous system. An apparent correlation was investigated between canonical 
Wnt signalling and the function of DISC1 in cell proliferation. Mao et al.19 observed an increase 
in proliferation rate in AHP culture when they added Wnt3a, and DISC1 knockdown neutralized 
this effect. Conclusions from these experiments were further strengthened by the investigation of 
the effect of DISC1 knockdown on transcription factors and target genes involved in Wnt/β-
Catenin signalling. Both gain-of-function and loss-of-function outcomes of DISC1 were tested, 
and they were found to have a positive and negative effect of neural progenitor proliferation, 
respectively19.   
 DISC1 knockdown caused defects in progenitor proliferation. However, β-catenin 
overexpression was able to correct the defects, suggesting DISC1’s modulating effect on β-catenin. 
β-catenin levels are known to be regulated by phosphorylation which is orchestrated by the kinase 
glycogen synthase kinase 3β (GSK3β). GSK3 phosphorylates the Ser33/37 and Thr41 residues 
of β-catenin. Phosphorylated -catenin is degraded via the ubiquitin-proteasome pathway26,27. 
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Observation of a decrease in the level of the aforementioned phosphorylation after DISC1 
knockdown raised the possibility of GSK3β involvement.  
 Understanding protein-protein interaction was the next necessary step to solve the puzzle 
of DISC1’s role in progenitor proliferation. Direct binding of DISC1 and GSK3β was established 
for a physiological interaction. Incubation with DISC1 fragment spanning peptide residues 1-220 
inhibited the phosphorylation of β-Catenin. This DISC1 fragment was further scrutinized for 
potentially independent conserved regions. Out of all of the shorter peptides tested, DISCtide-1 
(spanning 195-238 on mDISC1) was able to inhibit GSK3β. Determining the 44 amino acid long 
DISCtide-1 was a crucial discovery in understanding DISC1’s specific inhibition of kinase towards 
the phosphorylation of β-catenin19.  
Investigation performed by Mao et al.19 provides strong evidence of direct physical 
interaction between DISC1 and GSK3β in regulating neural progenitor proliferation. They 
determined the most potent inhibitory region on mDISC1 to be amino acids spanning from 195-
238 (and 193-236 in hDISC1, referred to as hD1) (Fig 1-2). The exact nature of interaction and 
the details of the GSK3β inhibition mechanism, however, remain elusive. DISC1’s direct and 
specific inhibition of GSK3β holds the potential for novel therapeutic research targeted for 
pathological conditions due to genetic mutations disrupting DISC1- GSK3β interaction. An 
essential criterion for any therapeutic research is to solve the detailed molecular framework 
involved in the protein-protein interaction. Our lab aims to understand the molecular framework 
required between DISC1 and GSK3β interaction using crystallography. 
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Figure 1-2. Neural progenitor proliferation and involvement of DISC1 in canonical Wnt/β-
catenin signalling. β-catenin is responsible for activating genes for neural progenitor proliferation 
after nuclear translocation. The picture on the left shows phosphorylation of β-catenin by GSK3β 
and degradation, limiting the rate of proliferation. The image on the right shows an active Wnt/β-
catenin signalling pathway where DISC1 acts as one of the regulators of GSK3β inhibition. A 44 
amino acid extended region in the N-terminal of DISC1 (hD1) is shown as the most potent inhibitor 
of GSK3β by Mao et al19.   
1.4 GSK3β: Structural basis of function, regulation, and relevance to Wnt-
signalling 
Glycogen synthase kinase 3β (GSK3β) was initially discovered to be one of the critical 
regulators for glycogen metabolism in the liver. Insulin triggers the glycogen deposition via 
initiation of dephosphorylation and activation of glycogen synthase28. The deactivation of 
glycogen synthase via phosphorylation is carried out by the GSK3β29. Once thought to have an 
important but narrow role in insulin mechanism, GSK3β was eventually established as a kinase 
involved with perhaps the most diverse cellular pathways. In addition to -catenin, almost 100 
other proteins have been experimentally implicated as GSK3β substrates to date, and theoretical 
kinase analysis predicted that the kinase could hypothetically have as many as 500 substrates30,31.  
 The GSK3β gene is conserved across species ranging from fungi and flies to mice and 
humans32,33. Extensive research into the role of this kinase revealed its involvement in an array of 
pathways other than the regulation of blood glucose. These pathways are directly linked to 
neuronal progenitor proliferation, cell proliferation, migration, etc., and have been implicated in a 
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multitude of diseases such as psychiatric illnesses, glucose metabolism disorders, and cancers34. 
Established as a regulator in many cell signalling pathways, GSK3β has been regarded as a classic 
therapeutic target. The kinase’s ubiquitous nature, however, poses a challenge for targeted 
therapeutics design. This problem can be circumvented by investigating regulation of GSK3β in a 
specific pathway.  
1.4.1 Fundamental regulatory mechanisms of GSK3β 
Three main regulation mechanisms are known to control the GSK3β kinase’s activity, each 
type being used by specific pathways. They are: (i) substrate preference for primed substrate, (ii) 
different phosphorylation states of the protein, and (iii) subcellular compartmentalization of the 
protein to different sites in the cell. Each of these regulatory functions is discussed below.  
1.4.1.1 The kinase activity of GSK3β is often specific towards a primed 
phosphorylated substrate 
GSK3β shows a significant preference specifically towards primed phosphorylated 
substrates35–37. The priming phosphorylation on GSK3β substrates happens on (P+4)th residue 
where P is the serine/threonine residue to be phosphorylated by GSK3β, and (P+4)th residue is a 
serine already phosphorylated by another enzyme prior to the GSK3β phosphorylation (Fig 1-3). 
The sequence of the primed phosphorylation site can be written as Ser/Thr-XXX-Ser(p), where 
the N-terminal Ser/Thr site is GSK3β target, and Ser(p) is primed phosphorylated site by another 
enzyme. This sequence specificity and preference is probably an evolutionary advantage that puts 
GSK3β at the intersection of major regulatory pathways. In Wnt/β-catenin signalling, priming 
phosphorylation of -catenin is accomplished by casein kinase Iα (CKIα) that phosphorylates -
catenin at Ser45. Then, GSK3β further phosphorylates the primed -catenin at 41, 37, and 33 
residues, marking it for ubiquitin-mediated proteolysis38–40. The sequence specificity towards a 
primed substrate is somewhat flexible. Some substrates with acidic/anionic residue instead of the 
primed phosphorylated group can also be processed as GSK3β substrates. The absence of priming 
phosphorylation from most of the GSK3β substrates has been shown to decrease the enzyme 
efficacy by ~100-1000 times41.  
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1.4.1.2 Regulation by different phosphorylation states of GSK3β 
GSK3 activity is modulated by two phosphorylation sites. Tyr216P aids to activate while 
Ser9P inhibits the enzyme. Tyr216P was found to be auto-phosphorylated under active 
conditions42,43. Recent research has suggested that Y216 phosphorylation may not be absolutely 
essential for activity as unphosphorylated GSK3β structure in an active conformation has been 
obtained by crystallography44. Nonetheless, the phosphorylated tyrosine residue plays a significant 
part in the stabilization of the activation loop45. The decrease in GSK3β activity by 5-10 fold has 
been noted by mutating Tyr216 to a non-phosphorylatable residue46. This suggests only a modest 
stimulation provided by Tyr216P, contrary to a ~1000-fold stimulation seen in other kinases.  
 A crucial negative regulation of the kinase is brought about by phosphorylation of Ser9 
residue in the N-terminus. This regulation was discovered to be used by the insulin mechanism via 
PKB/Akt47,48. Prephosphorylated primed substrates were found to interact with Arg96 in the 
substrate binding cleft of the kinase44. Site specific mutations and crystallographic models proved 
that the phosphorylated Ser9 of the N-terminal segment binds to the Arg96 residue of the substrate-
binding cleft in GSK3β, posing as a pseudo-substrate (Fig 1-3)49,44. Binding of the pseudo-
substrate blocks the access of primed substrates to the substrate binding cleft, auto-inhibiting the 
kinase.  
 Research published by Mao et al.19 showed DISC1 knockdown resulted in a significant 
increase in Tyr216P in GSK3β. Ser9P levels in the kinase were not affected. The overexpression 




Figure 1-3. Substrate specificity and regulatory mechanisms of GSK3β. (a) Schematic 
representation shows the possible conformational change in the substrate-binding pocket after Tyr 
216 residue is phosphorylated. This could explain some level of increase in the binding efficiency 
of primed substrates to the kinase with the Tyr216P. (b) Serine/threonine kinase GSK3β mostly 
shows specificity towards the primed substrates where priming phosphorylation by another kinase 
has taken place at (P+4) serine residue, where P is the site of phosphorylation by GSK3β. Three 
basic residues, Arg96, Arg180, and Lys205, show interaction towards the primed phosphorylated 
site and help stabilize the substrate in substrate binding pocket. (c) While Tyr216P has been 
associated with active conformation of the kinase, a negative regulation via phosphorylation of Ser 
9 residue also exists. Ser9P leads to the serine residue acting as a pseudo-substrate towards the 
substrate-binding pocket, blocking the access of other substrates. The image design is based on a 







1.4.1.3 Regulation by subcellular compartmentalization 
 Subcellular compartmentalization is another important regulatory mechanism of GSK351. 
By associating with different complexes, the activity of GSK3 is restricted to substrates residing 
in these complexes. As will be discussed further below, subcellular compartmentalization is a 
critical regulatory mechanism of GSK3β in the Wnt signalling pathway.  
1.4.2 GSK3β at the molecular intersection of Wnt/β-catenin signalling 
A GSK3β homolog in Drosophila (known as Zeste-white3 or Shaggy) was implicated as a 
critical component of Wingless Wg/Wnt signal transduction52. Canonical Wnt-signalling pathway 
in humans is a major pathway involved in cell growth, differentiation, and migration, especially in 
the brain53. Humans have genes responsible for 18 different Wnt molecules, all of which contain 
conserved cysteine residues and glycosylation as part of the post-translational modification 
(molecular weight range between 39 to 46 kDa)53. This pathway involves activation of a signalling 
cascade by Wnt that leads to stabilization and nuclear localization of β-catenin, a co-activator of 
TCF/LEF family of transcription factors. Activation of T-cell factor/lymphoid enhancer-binding 
factor (TCF/LEF)-bound genes initiate neural progenitor proliferation54. 
In the absence of Wnt signalling molecules, ubiquitous GSK3β overphosphorylates the N-
terminal of β-catenin. β-catenin phosphorylation leads to ubiquitin-mediated proteasomal 
degradation, thus stopping the nuclear localization of the molecule and halting the neuronal 
progenitor proliferation26. Destruction of β-catenin via phosphorylation is a very complicated 
process. It is carried out by subcellular compartmentalization of a complex known as “β-catenin 
destruction complex,” and it comprises scaffold proteins such as Adenomatous polyposis coli gene 
product (APC) and Axin55,56. In the absence of Wnt signalling molecules, these two scaffold 
proteins orchestrate a large protein complex via direct interaction with Casein Kinase 1α (CK1α), 
GSK3β, and β-catenin. The two kinases of this Axin-APC-orchestrated β-catenin phosphorylation 
and destruction processes are CKIα and GSK3β40,57,58. As described earlier, CK1α performs 
priming phosphorylation on β-catenin at Serine 45 residue, prompting GSK3β phosphorylation at 
residues 41, 37, and 33. E3 ubiquitin ligase β-TrCP recognizes phosphorylated β-catenin and 
marks it for ubiquitination and proteasomal degradation26,59,60. The stage of β-catenin destruction 
complex set by APC-Axin could be a reason why GSK3β is such a widely expressed enzyme with 
little or no obstruction of one pathway with the other (Fig 1-4). 
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In the presence of Wnt signalling molecules bound to their receptors, the -catenin 
destruction complex is disassembled. As a result, CKIα and GSK3β no longer phosphorylate -
catenin. Unphosphorylated -catenin is stable, and it accumulates in the cytoplasm. Excess β-
catenin in the cytoplasm translocates to the nucleus and acts as a co-activator of genes responsible 
for cell proliferation. The canonical Wnt/β-catenin signalling pathway is a very intricately 
designed complex pathway. The exact cascade involved in disassembling the Axin-APC complex 
is still obscure, although there are some established vital players (Fig 1-4). 
Wnt molecules interact with two sets of co-receptors during active Wnt-signalling: (a) the 
frizzled receptor (FZD) that spans the plasma membrane seven times and (b) the low-density 
lipoprotein receptor-related protein 5 or 6 (LRP5/6) that spans the plasma membrane only once61–
66. Binding of Wnt molecule to these two receptors leads to activation and sequestration of 
downstream effectors. A critical effector of the pathway is Dishevelled (DVL 1-3 in humans). Its 
mutation in animal models was lethal as their loss severely hampered Wnt signalling67. DVL (~700 
amino acids) serves as a hub via interaction of its different domains with different proteins. Three 
important domains (~80-90 amino acids each) of DVL are DIX (Dishevelled, Axin), PDZ 
(Postsynaptic density 95, discs large, zona occludens-1), and DPE (Dishevelled, Egl-10, 
Pleckstrin). The carboxy-cytosolic region of FZD receptor sequesters the PDZ domain of DVL 
when Wnt signalling is active68,69. Recent developments show the affinity of DPE domains for the 
phospholipids of the plasma membrane as well as for some protein interactions. The DIX domain 
of DVL is capable of forming homo-dimers/oligomers as well as hetero-dimers with Axin, which 
also has a DIX domain for interaction70–72. (Fig 1-4).  
The hetero-dimers of DVL-Axin via interaction of their DIX (DAX in Axin) domains could 
be one of the many ways how Wnt-signalling disrupts the β-catenin destruction complex. Axin 
acts as one of the critical scaffolds in the absence of Wnt and provides a stage for GSK3β and 
CKIα for over phosphorylation of β-catenin. Sequestration and isolation of Axin to the plasma 
membrane by DVL may be interrupting the physiological proximity required by the destruction of 
complex partner proteins.  
The PPPSxS motif on LRP6 is also known to be phosphorylated by GSK3β and CKIα in 
the presence of Wnt molecules. The phosphorylated LRP6 motif in the cytoplasm is a docking site 
for Axin73–76. Binding of Axin to the phosphorylated LRP 5/6 cytosolic PPPSxS motif and DVL 
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mediated Axin dimerization could be happening simultaneously, according to a classic 
biochemical model77. The destruction complex clogged model suggests transport of the whole 
Axin-APC destruction complex to the plasma membrane where β-catenin is still loaded but trapped 
in the complex. This could lead to stabilization of new β-catenin in the cytosol despite undisturbed 
integrity of the β-catenin destruction complex in the cell in the presence of Wnt78. The Axin auto-
inhibition model focusses on the dephosphorylation of Axin in the wake of active Wnt/β-catenin 
signalling by Protein Phosphatase I (PP1). Axin is phosphorylated by GSK3β in canonical Wnt/β-
catenin signalling. However, a correlation has been established between β-catenin stabilization, 
Axin dephosphorylation by PP1 in the presence of Wnt, and Axin phosphorylation in the absence 
of Wnt. The Axin auto-inhibition model suggests the inability of dephosphorylated Axin to sustain 







      
 
Figure 1-4. Canonical Wnt/β-catenin signalling pathway. (a) The picture on the left describes 
the overall mechanism of neural progenitor proliferation in the absence of Wnt/β-catenin signalling 
molecules. A β-catenin destruction complex via scaffold proteins such as APC and Axin is 
arranged. The destruction complex uses the kinase function of GSK3β to over phosphorylate β-
catenin, once CK1α primes it. The phosphorylated β-catenin gets degraded via ubiquitin-mediated 
proteasome using βTrcp. (b) Schematics on the right describe the positive regulation of progenitor 
proliferation once Wnt binds to the co-receptors Frizzled (FZD) and LRP 5/6. Multiple theories of 
disassembly of β-catenin destruction complex have been suggested. Possibly, the interaction of 
Dishevelled (DVL) with FZD, Axin heterodimerization with DVL via DIX domain, and Axin 
sequestration via LRP 5/6 could be disrupting the destruction complex. This leads to cytosolic 
accumulation and nuclear accumulation of β-catenin, thus switching on genes for proliferation.  
1.4.3 Emergence of FRAT1 as a potential regulator of GSK3β in Wnt signalling 
Cytoplasmic complexity of the canonical Wnt/β-catenin signalling has been long studied. 
Involvement of multitude of factors makes it difficult to announce a complete model of GSK3β 
inhibition and β-catenin stabilization during the active state of Wnt-signalling. Discovery of a new 
causative gene Frequently rearranged in T-cell lymphomas 1 (FRAT1) from mouse T-cell 
lymphomas led to a series of investigations that established the Frat1 protein to be involved in the 
dissociation of Axin-APC β-catenin destruction complex83. The Frat1 homologous gene/protein in 
Xenopus called GSK-3 binding protein (GBP) was identified as one of the key positive regulators 
in Wnt-dependent regulation of β-catenin stability84. A detailed investigation of the physiological 
placement of Frat1 in the dissociation process of Wnt-dependent β-catenin destruction complex 
(a) Wnt OFF (b) Wnt ON 
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revealed the presence of a quaternary complex involving GSK3β, Axin, DVL as well as Frat185. 
This quaternary complex was comparatively less stable than the Axin-APC destruction complex. 
Li et al.85 established a more robust and stable complex formed by just Frat1 and GSK3β. Later 
studies have strongly suggested a mutually exclusive complex formation of Axin-GSK3β and 
Frat1-GSK3β, which may be counteracting each other’s role in β-catenin stabilization86.  
Interaction of Frat1 and GSK3β garnered a lot of attention regarding its peculiar inhibition 
of the kinase. In vitro studies revealed that an N-terminal peptide spanning residues 188-226 on 
Frat1 (referred to as FRATide) was able to inhibit GSK3β interaction and phosphorylation with 
Axin and β-catenin. They also identified this interaction to be very specific towards the canonical 
β-catenin stabilization substrates. FRATide was unable to inhibit GSK3β kinase action towards 
common substrates such as Glycogen Synthase (GS)41. These findings repeatedly establish the 
presence of a specific GSK3β inhibition mechanism in place for canonical Wnt/β-catenin 
signalling. 
1.4.4 Literature review of relevant crystal structures of GSK3β 
1.4.4.1 Overall structure 
The serine-threonine kinase GSK3β maintains a usual protein kinase structure, an N- 
terminal β-sheet domain and a C- terminal α helical core87. The GSK3β gene is present in human 
chromosome 3 and has 11 exons that translate to a protein with molecular weight ~47 kDa. The 
N-terminal β-strand domain, also known as β-barrel due to its unique arrangement, spans from 
residues 25-13945. The C-terminal α-helical core domain lies between residues 139-343. The C-
terminal residues from 344 to 382 contain small α-helices and lies outside the core kinase domain. 
Amino acids from 1-25 and 382-420 are thought to be disordered for structures obtained from 
crystallographic analysis88.  
The N-terminal segment of the kinase is mainly comprised of seven anti-parallel β-strands, 
where the strands 2-6 form a β-barrel44. A short α-helix (residue 94-104) (C-loop) connects β-
strands 5 and 6 in the N-terminus. Arg96 of the C-loop is an essential part of the catalytic domain 
that helps position the primed substrate. The α-helical core domain retains structural integrity 
similar to other MAP kinases44. Residues following 343 until 384 contain secondary structures that 
include a β-turn from 350-353 and short α-helices between 363-368 and 373-378. These structures 
are packed against the large α-helix formed by 155-175 residues of the core domain44,45,88. 
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1.4.4.2 Structural details of GSK3β involved in kinase activity and substrate 
specificity 
The crystal structure of Tyr216P-containing GSK3β revealed an interaction of the tyrosine 
residue with Arg220 and Arg223. Tyr216P in GSK3β has been compared to Tyr185P in ERK2, 
another kinase of the same class. However, the tyrosine residue in GSK3β shows a broader opening 
of substrate binding groove which could be responsible for a larger number of substrates of the 
kinase and the stabilization of the substrate-binding pocket (Fig 1-5)45. 
 The kinase activity of GSK3β would solely rely on careful positioning of catalytic groups 
and substrate so that there are energy and stereo-favourable transfers of ϒ-phosphate from ATP to 
Ser/Thr of the substrate side chain89. Most of the protein kinases become active due to interaction 
between the basic residues of the N-terminal and the catalytic groups with the phosphate ion of the 
activation segment. Three basic residues, Arg96, Arg180, and Lys205, were determined to bind to 
the primed phosphorylated site of the substrate44,45,88. This was further proven by the inability of 
the kinase to phosphorylate primed substrates when Arg96 was mutated to an alanine49. Thus, 
these three residues coordinate the phosphorylated primed serine of the substrate and stabilize the 
substrate binding. These sites would also interact with Ser9P during inhibitory regulation and 
block the entry of primed substrates. GSK3β aligns both of its domains using primed 
phosphorylated serine of the substrate and its interaction with the basic residues (Arg96/180, 
Lys205) (Fig 1-5). ATP binding region of the kinase is bordered with the glycine-rich loop and 
the hinge88. GSK3β structures also revealed an interaction of the anionic group with -NH backbone 
group of Val214 along with the Tyr216 in the activation loop. This loop (residues 200-226) 
outlines the activation loop. Once phosphorylated, Tyr216 residue undergoes a sizeable 
conformational change so that the side chain is exposed to other amino acids. The Tyr216P position 




Figure 1-5. Three-dimensional structure of GSK3β. The cartoon model of the kinase is derived 
from the PDB model 1H8F. The overall structure of the protein shows a clear distinction of N-
terminal β-barrel (coloured red), C-terminal α-helical domain (coloured cyan), and a terminal chain 
of small helices in the back (coloured wheat). The box shows the enlarged structure of the 
substrate-binding domain and activation loop (magenta, residues 210-220) that is sandwiched 
between N- and C-terminus. Arg96 from C-loop (yellow) from N-terminal and two basic residues 
from C-terminus (Arg180 and Lys205, one of them from the activation loop) show direct 
interaction with the sulfonate anion present (in the substrate-binding pocket) in the structure above. 
These residues interact with the primed phosphorylation site on the substrate. A polar interaction 
with a water molecule (green ball) is also seen in the pocket. Tyrosine at 216 position is 
unphosphorylated and is marked as the green residue in the middle of the magenta activation loop.  
1.4.4.3 The structural framework involved in Axin GID-GSK3β 
GSK3β directly interacts with Axin and is involved in the formation of Axin-APC 
complex. Binding of the GSK3β to Axin-APC scaffold has shown a ~20,000-fold increase in β-
catenin phosphorylation. Detailed interaction between a minimal GSK3β binding region on Axin 
(residues 383-401, known as Axin-GID) and GSK3β is discussed in this section. Genetic and 
biochemical studies suggested overlapping binding sites for FRAtide and Axin-GID on GSK3β. 
A comparison of the binding sites and types of interaction for both FRATide- GSK3β and 
AxinGID- GSK3β complexes is discussed in the next section.  
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The Axin-GID forms a single α-helix that comprises a mixture of both hydrophobic and 
hydrophilic residues (Fig 1-6)46. Unlike FRATide, Axin-GID forms a single helix without a break. 
The interaction framework involves a hydrophobic surface channel that involves two main regions 
on GSK3β, (i) an α-helix in C-terminal between 262-273 and (ii) a loop between 285-299. One 
side of the hydrophobic groove comprises of hydrophobic interaction between Axin residues 
Phe388, Leu392, Leu396, and Val399 and GSK3β residues Val263, Leu266, Val267, Ile270 (the 
α-helix). Interactions on the opposite wall involve Axin residues Pro385, Ala389, Ile393, and 
Leu396 packed with GSK3β residues Tyr288, Phe291, Pro294, and Ile296. Although most of the 
interactions between Axin-GID and GSK3β are hydrophobic, some polar interactions play a key 
role as well. Hydrogen bond and ionic interaction are observed between Arg395 of Axin-GID and 
Asp264 of GSK3β. A hydrogen bond is formed between Gln400 of Axin-GID and Gln295 of 
GSK3β. Axin binding to the C-terminal of GSK3β also prevents dimerization of the kinase under 
micro-molar concentration46.  
The discussion above shows a common interaction region on GSK3β by both FRATide 
and Axin-GID, the α-helix (262-273) and the loop (285-299) in the C-terminal. One of the major 
differences between FRATide and Axin-GID is the presence of a sharp turn with a break in the 
former. FRATide shows a sharp turn between the residues Gly210 and Asn211 (Fig 1-7). This 
allows a hydrogen bond between FRATide and Tyr288 and Glu290 of GSK3β. Absence of this 
break in Axin-GID results in a hydrophobic interaction instead. This interaction is observed 




Figure 1-6. GSK3β-Axin GID complex. Crystal structure of the binary complex between kinase 
GSK3β and minimal GSK3β binding region on Axin (Axin-GID peptide) was recorded at a 
resolution of 2.4 Å. The cartoon model with detailed interaction framework is based on the PDB 
model 1O9U (published by Dajani et al. (2003)). The Axin-GID forms a single amphipathic α-
helix (shown in cyan) and interacts with 2 major regions of C-terminal of the kinase, (i) an α-helix 
formed between GSK3β residues 262 to 273 (shown in light pink) and (ii) a loop between residues 
285-299 (shown in green). The boxed portion on the right highlights the major interaction sites on 
both protein and peptide. One of the two major hydrophobic interaction sites is formed between 
Phe388, Leu392, Leu396, Val399 of Axin-GID on one side of the peptide with Val263, Leu266, 
Val267, Ile270 of GSK3β. The other site is between the other side of the Axin-GID peptide 










1.4.4.4 Structural framework involved in the binary complex of FRATide-GSK3β   
Crystal structure of FRATide (197-222)-GSK3β complex was obtained by Bax et al. The 
molecular framework involved in the FRATide-GSK3β complex is mainly sustained via 
hydrophobic interactions with significant support from hydrogen bonds and van der Waals 
interactions45. FRATide binds at the C-terminal domain of GSK3β. FRATide bound GSK3β shows 
a substantial displacement between the loop spanning residues 288-294 and the α-helix spanning 
262-273, leading to the formation of a hydrophobic groove (Fig 1-7). FRATide is comprised of 
two helices where the helix-turn-helix contains α1 and α2 (the break is between Gly210 and 
Asn211). The α1 helix (Histidine at 200 position of FRAT1) remains proximal to the Tyr216 on 
GSK3β but is less buried in the hydrophobic groove. The α2 helix interacts primarily with the 
hydrophobic groove on GSK3β. Lys271 of GSK3β forms van der waals interaction with FRATide 
via its hydrophobic side chain regions. Leucine and isoleucine at the N-terminal of the α2 helix 
(residue 212 and 213) are crucial to the interaction process where they form hydrogen bonds with 
side chains of Tyr288 and Glu290 on GSK3β (Fig 1-7)84. The leucine and isoleucine from 
FRATide are the only conserved residues in GID from Axin. Initially, it was hypothesized that 
they compete against each other to bind GSK3β as they share a partial binding site (based solely 
on the Leu-Ile sequence as they share no homology for any different amino acid sequence). The 
kinetic analysis showed a competition of FRATide and GID for GSK3β with less affinity between 
GID and GSK3β, which could explain why FRATide is able to dissociate Axin-APC complex 
from GSK3β.  
A comparison of GSK3β structures in complex with peptides (Axin-GID and FRATide) 
from canonical Wnt/β-catenin pathway may give us insight into the binding mechanism between 
GSK3β and hD1 (minimal GSK3β binding and inhibiting peptide of DISC1, 44 amino acid long), 




Figure 1-7. FRATide-GSK3β complex. Schematics of the GSK3β-FRATide complex shown in 
the cartoon model, based on the PDB model 1GNG. FRATide (shown in light pink) binds to 
GSK3β in the C-terminus region (shown in orange, yellow, and cyan). The interaction does not 
affect the substrate-binding pocket or the activation loop. A phosphorylated Tyr216 can be seen in 
magenta (in the activation loop). FRATide interacts mainly with residues 285-310 on GSK3β 
(shown in cyan). A helix-turn-helix is seen with FRATide (α1 and α2). Mostly hydrophobic 
interactions are observed between Leu212, Ile213 (FRATide) and Tyr288, Glu290 (GSK3β). A 
van der waals interaction is seen between α2 helix of FRATide and Lys271 of GSK3β. Overlay of 
GSK3β and GSK3β+FRATide structure shows the creation of a hydrophobic groove (shown in 
the bottom picture). This groove in GSK3β is created when the loop 288-294 moves around 6.4 Å 





1.5 In vitro analysis of hD1 binding to GSK3β 
Our lab has investigated the mechanism and molecular framework behind the interaction 
between synthetic hD1 and GSK3β using a variety of biochemical and biophysical assays90. SPR 
(Surface plasmon resonance) studies showed that FRATide can still bind GSK3β that has been 
saturated with hD1. The SPR assays suggested different binding sites for these peptides on GSK3β.  
Further investigation of this finding was done using an enzymatic assay. hD1 can inhibit 
GSK3β at an IC50 of ~3 μM. Surprisingly in the presence of FRATide, the inhibitory effect of 
hD1 on GSK3β is suppressed. This finding hints towards a possible overlap of interaction sites for 
both peptides on the kinase, contradictory to the SPR findings. 
These opposing inferences could be explained by findings shown by Mao et al.19 They 
discovered a minimal GSK3β binding sequence (spanning 15 amino acids, 211-225 of mouse 
DISC1 protein) via SPR experiments. This minimal GSK3β binding sequence did not show any 
inhibitory effect on the kinase. Further experiments by our lab confirmed that the conserved 
minimal GSK3β region on hD1 of the human DISC1 protein binds but does not inhibit GSK3β 
(referred to as GSK3β binding region, GB, 209-225). Deletion experiment showed that the kinase 
inhibitory region resides at the C-terminal end of hD1 (referred to as GSK3β inhibitory region, GI, 
spanning 226-236) 
Based on the SPR, enzymatic assays, and the findings mentioned in the previous paragraph, 
two possible models were proposed for the interaction framework of FRATide, hD1, and GSK3β. 
The first one hypothesizes that the FRATide physically blocks the “GI” binding site on GSK3β 
but not the “GB” binding site. The other model predicts a conformational change of the “GI” 
binding site but only once FRATide binds to GSK3β. These two models are the most likely 
scenarios given that FRATide and hD1 can both bind the kinase simultaneously, but FRATide 
prevents hD1 inhibition of GSK3β. FRATide is known to change conformation on GSK3β to 





Figure 1-8. Predicted model FRATide and hD1 interaction with GSK3β. In vitro experiments 
have shown proofs of two regions on hD1, a central GSK binding region “GB” and a C-terminal 
inhibitory interacting domain “GI”. FRATide prevents hD1 mediated GSK3β inhibition by either 
physically blocking the GI binding site on GSK3β (while allowing the GB to bind) or changing 
the conformation of GI binding region by binding elsewhere.  
 However, these models only predict the possible scenarios and offer essential cues for 
future investigation to determine the exact binding site. Detailed crystallography based structural 
analysis will be able to provide a final answer. This calls for structural investigation using 
crystallization of GSK3β-hD1 complex.  
1.6 Hypothesis 
Based on the models described above (Fig 1-8), I hypothesize that GB and GI regions of 
hD1 directly bind to GSK3β but binding of FRATide to hD1-GSK3β complex results in 
impairment of hD1-GI binding to GSK3β, preventing the inhibitory action of hD1.  
1.7 Objective 
The crystallographic analysis of the hD1/GSK3β complex may reveal the hD1 interacting 
region on GSK3β. The objective of my project is to crystallize the GSK3β & hD1 protein complex  
with and without FRATide. X-ray crystallography will be used for structural investigation. I have 
tried to achieve the objective using the following strategies, described and discussed in detail in 
chapters 3, 4 & 5.  
Strategy 1: Complex formation of HisMBP- hD1with GSK3β 
Strategy 2: Complex formation using GSK3β- hD1 co-expression construct 







2 Chapter 2: Materials and Methods 
2.1 Overview 
 The current section describes the cloning, overexpression, purification and crystallization 
techniques to achieve the target protein complex. This chapter is divided based on techniques with 
sub-sections titled with individual recombinant proteins or peptides used for the project. Two 
methods of cloning were used e.g., traditional restriction enzyme based cloning and ligase 
independent cloning to clone the human sequences of proteins of interest into plasmids for 
bacterial expression systems. Overexpression and purification protocols mentioned for each 
protein in this section were optimized via a series of experiments to yield pure and high quantities 
of proteins. Finally, complex formation for each strategy and the corresponding crystallization 
trials are described.  
2.2 Rationale 
Molecular understanding of any protein complex structure requires structural biology 
methods such as X-ray crystallography. Critical criteria for this method are the high quantity and 
purity of the purified protein (complex). Among all protein expression systems available, bacterial 
systems provide more flexibility, higher expression levels, and ease of purification. Different 
cloning methods use different strategies to derive a protein complex; for example, mono-cistronic 
plasmids allow expression of a single protein from one system. In contrast, a polycistronic plasmid 
allows expression of multiple proteins (possibly a complex) from a single system. Many 
chromatography techniques, such as affinity, ion exchange, size exclusion, etc., use different sets 
of principles to separate the target protein of interest from most of the contaminants. Many 
contaminants resistant to one type of chromatography could be removed by another. We have used 
various combinations of chromatography techniques for purification of different complexes. The 
quality of the protein complexes is evaluated by gel filtration, western blot, and dynamic light 
scattering (DLS) before crystallization. All catalogue numbers are listed in Appendix A.  
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2.3 Peptide: hD1 
 The synthetic peptide (residue 193 to 236) hD1, derived from the full-length human DISC1 
(gene ID- 27185) (Uniprot- Q9NRI5.3), and it was purchased from NEO Biolabs (Cat. P12485D, 
96.5% purity). The 44 amino acid long peptide has a molecular weight of 4.53 kDa and an 
isoelectric point of 4.75. The sequence of the peptide is (193) PEVPPTPPGS HSAFTSSFSF 
IRLSLGSAGE RGEAEGCPPS REAE (236) of the hDISC1 protein. 
2.4 Peptide: FRATide 
Synthetic FRATide (residues 174-196) peptide sequence was derived from the full-length 
human FRAT1 gene (Gene ID- 10023) (Unirpot-Q92837). The 25 amino acid-long peptide has a 




The sequence coding for hD1 (44 amino acids, residues 193-236) from hDISC1 (Gene ID: 
27185) (854 amino acids) was cloned into a T7-promoter based protein expression system (pST44) 
with ampicillin resistance gene as a selective marker. The vector contains a 6x histidine tag 
(6xHis), a maltose-binding protein tag (MBP), and a tobacco etch virus (TEV) protease cleavage 
site (amino acid sequence ENLYFQ-S). Ligation independent cloning was used to clone the hD1 
sequence into the vector C-terminal to the 6x His, MBP, and TEV protease site.  
The vector was linearized using the restriction enzyme SspI-HF (NEB: R3132S) in the 
presence of cut smart buffer (NEB: B7204S). The hD1 coding sequence on hDISC1 was amplified 
using the protocol from table 2-1. Linearized vector and PCR products were confirmed by a 1.5% 









Table 2-1. The PCR protocol for the amplification of hD1 sequence from the hDISC1 gene. 
Step Temperature (̊C) Time 
Initial denaturation 98 ̊C 30 s 





6 s (for 172 nucleotides) 
Final extension 72 ̊C 2 mins 
Hold 4 ̊C  
The primers used for PCR are as mentioned below  
Forward primer- 5’ TAC TTC CAA TCC AAT GCA CCG GAA GTG CCG CCGAC 3’ 
Reverse primer- 5’ TTA TCC ACT TCC AAT GTT ATT ATT CAG CTT CGC GAC TCG 3’ 
Ligation independent cloning (LIC) method was used to yield the final construct (Fig 2-
1)91. This cloning method uses T4 DNA polymerase and specially designed constructs. T4 DNA 
polymerase is capable of both exonuclease and endonuclease activities. The exonuclease activity 
of the polymerase is triggered in the absence of dNTPs, and it is used to create cohesive ends. After 
incorporating a restriction site in the construct, the overhang is designed in a way that it will miss 
a specific nucleotide for at least 15 bases. In this construct, the nucleotide bases are guanine and 
cytosine in the positive and negative strands, respectively. These initially missing nucleotides 
create the boundary of the cohesive ends. First, the construct was linearized by the restriction 
enzyme, creating blunt ends. Next, a T4 DNA polymerase reaction was performed with only one 
dNTP that was complementary to the boundary nucleotide. In the absence of complementary 
dNTPs, the 3’→5’ exonuclease activity of T4 DNA polymerase would dominate until it slided to 
the boundary location where the one dNTP was present for the polymerase activity to take over. 
As a result, a cohesive end of 15 bases was generated.   
An insertion PCR overhang with a pairing sequence for the vector overhang is also created 
using the same principle as previously described. The annealing of the T4-treated PCR product 
and the vector was done at a ratio of 3:1 and transformed into competent bacteria. The nicks present 
at the overhang joining sites were ligated by bacterial ligases in vivo. This process used neither the 
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restriction endonucleases to create overhangs nor the externally provided ligases for ligation. The 
detailed protocols are pictured below.  
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Figure 2-1 Ligation independent cloning. (a) The cleavage site for restriction endonuclease sspI-
HF. SspI recognizes this specific sequence on the pST44 vector. SspI site is located after the 
sequence for 6xHis and TEV cleavage site. (b) The flowchart shows cleavage of a vector at the 
sspI site. The restriction digestion creates a linearized sequence with blunt ends. T4 DNA 
Polymerase creates an overhang using exonuclease activity. The exonuclease activity is limited by 
the supply of dGTP, which switches on the polymerase activity at the first cytosine on the negative 
strand. (c) PCR products are treated with T4 DNA polymerase and dCTP. An overhang is created 
at the first Guanine on the positive strand. (d) The last figure shows the annealing of the matching 
sequence of the PCR product and the vector. The final ligation happens inside the bacterial cells 







 Transformed colonies were tested for successful cloning by colony PCR using the 
following protocol (Table 2-2) 
Table 2-2.  Contents and protocol for colony PCR. 
Content Volume 
10X ThermoPol Reaction 
Buffer 
2.5 μL 
10mM dNTPs 0.5 μL 
10 μM Forward primer 0.5 μL 
10 μM Reverse primer 0.5 μL 
Colony Pipet tip full 
Control plasmid  
H2O 20.875 μL 
Taq Polymerase 0.125 μL 
Step Temperature (C) Time Number of cycles 
Initial Denaturation 95 5 mins  1 
Denature 95 15 s 30 
Annealing (primer 
Tm) 
62 15 s 30 
Extension (1 min/kb) 68 20 s 30 
Final extension 68 5 mins 1 
Hold 4 Infinite 1 
 
The final protein sequence of the construct is as follows, with the names of the tags or 
























 The sequence for the human GSK3β (Gene ID: 2932, NCBI) was cloned into a T7 
promoter-based pST50Trc1 vector backbone with ampicillin resistance as the selective marker92,93. 
A 6x histidine (6xHis) and TEV protease cleavage site sequences (TEV) are present N-terminal to 
the GSK3β sequence.  
 His-GSK3β contains 447 amino acids with a molecular weight of 49.40 kDa and an 
isoelectric point of 8.85. The protein sequence of the protein is as follows, with tags bolded and in 










Figure 2-3. Graphic map of genetic sequence for His-GSK3β. 
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2.5.3 Co-expression construct HisGSK3β-StrnhD1 
 Single T7 promoter based polycistronic pST44 vector backbone was used to clone 
sequences for both proteins of interest, hD1 and GSK3β93. The 6xHis and streptavidin (Strn) tags 
were present upstream of GSK3β and hD1 coding genes, respectively. The ampicillin resistance 
gene is used for selective growth marker. The polycistronic vector backbones were developed by 
Tan et al. (2004) to provide modularity for expression of multiple recombinant proteins in one 
vector. This system uses conventional digestion and ligation of multiple genes from pST50Trc1/2 
vectors into four serial gene cassettes available in the pST44 vector. Each cassette also contains 
sequence coding for cleavable or uncleavable affinity tags on either side of the genes of interest. 
A total of up to 4 different genes can be cloned into the final backbone for protein expression under 
a T7 promoter system. Every gene is flanked by various restriction enzyme digestion sites on both 
5’ and 3’ ends. A schematic of the polycistronic protein expression system is depicted in figure 2-
4.  
 The hD1 coding sequence was PCR amplified from the full-length DISC1 plasmid by using 
the following primers and Q5 Hot start high-fidelity DNA polymerase (NEB: M0493L) 
Forward primer- 5’ GCT AAA GGA TCC CCG GAA GTG CCG CCG A 3’ 
Reverse primer- 5’ GGG CCC TGT ACA TCA TTC AGC TTC GCG ACT CG 3’ 
 The PCR product was cloned into the pST50Trc2 backbone vector using NdeI (NEB: 
R0111S) and BsrGI (NEB: R0575S) in the presence of NEBuffer 2.1 (NEB: B7202S), downstream 
to a sequence coding for Streptavidin tag (Strn). The human GSK3β clone in the pST50Trc1 
backbone was already made (Fig 2-3)93. The HisGSK3β sequence and the Strn-hD1 sequence were 
digested out from their respective vectors and cloned sequentially into the pST44 backbone using 
the XbaI (NEB: R0145S) &BglII (NEB: R0144S) sites for HisGSK3β and the EcoRI (NEB: 
R0101S) & HindIII (NEB: R0104S) sites for Strn-hD1 in the presence of NEBuffer 2.1 (Fig 2-4). 
The two genes of interest were cloned into the cassette 1 and 2 of the pST44 vector one at a time 
(Fig 2-4). T4 DNA ligase (NEB: M0202S) in the presence of T4 DNA ligase buffer (NEB: 
B0202S) was used to ligate 3:1 molar ratio of the inserts and vectors. The cloned construct was 








Figure 2-4. Polycistronic system for co-expression construct. (a) Schematics of pST44 
polycistronic protein expression system. This system uses four transfer plasmids named as 
pST50Trc1/2 to transfer four different genes into the pST44 expression system. All transfer 
plasmids contain target clone region flanked by an internal set of restriction enzymes, NdeI and 
BsrGI. Outside of this region are the restriction sites that help to transfer the whole gene. All 
restriction sites are unique and highlighted in different colours for a different gene. Ɛ- Translation 
enhancer, SD- Shine-Dalgarno sequence, Arrows in pST44- primer sites, Blue, green, orange, red- 








The clone with the confirmed sequence was used for protein expression using BL21 Star 
(DE3) competent cells (source: Dmitriev lab, CoM, USask). Optimized growth parameters are 
listed below: 
Table 2-3. Overexpression parameters variation for His-MBP-hD1 expression. 
Flask (for both 
clones) 
IPTG concentration Temperature Duration of growth 
Post induction 
1 1 mM 37 ̊ C 3 hrs 
2 0.5 mM 25 ̊ C ON 
3 0.2 mM 15 ̊ C ON 
  
Cells were grown using 50 mL of 2xYT media (16 g tryptone, 10 g yeast extract, 5 g NaCl 
per 1 L of media, pH 7.0, Ampicillin at 100 μg/mL) in 250 mL Erlenmeyer flasks (Corning: 4980-
250) and shaken at 220 RPM. The optimized purification protocol required growth at 37 ̊ C for 3 
hours after induction with 1 mM IPTG at OD600 range of 0.4-0.6. The cells were spun down at 
5000 RPM, at 4 ̊ C in 50 mL conical tubes (Fisher: 430044), using an Allegra 25R centrifuge (TS 
5.1-500 rotor). Cell pellets were flash-frozen with liquid nitrogen and stored at -20 ̊ C. 
2.6.2 His-GSK3β 
Protein was overexpressed using BL21 Star (DE3) pLysS cells. Seed culture was grown 
with 15 mL of Lysogeny broth (LB) media (10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract, pH 
7, 100 μg/mL ampicillin, 25 μg/mL chloramphenicol) in a 50 mL conical tube at 30 ̊ C. A 1:1000 
ratio was used to inoculate seed culture to main culture media. TB media (24 g/L yeast extract, 20 
g/L tryptone, 4 mL/L glycerol, 100 mL/L phosphate buffer (0.17 M KH2PO4, 0.72 M K2HPO4)) 
in the presence of ampicillin (100 µg/mL) was used for protein overexpression in the main culture. 
A total of 12 L media would be grouped in 8 Ultra yield Thomson flasks (1.5 L media in each 3 L 
flask) for one batch of overexpression. The culture was induced for protein expression using 0.1 
mM IPTG when the OD 600 value was 0.2 and the temperature was 18 ̊ C. Cells were grown for 
48 hours with ampicillin replenished after the first 24 hours. Cells were harvested by spinning the 
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culture at 4700 RPM using 2 L PPCO Nalgene centrifuge bottles in a Sorvall RC12BP low-speed 
centrifuge (H-12000 swinging bucket rotor) (4 ̊C, 30 minutes). Cell pellets were flash-frozen with 
liquid nitrogen.  
2.6.3 HisGSK3β-StrnhD1 (Co-expression construct) 
The clone with the confirmed sequence was first optimized for the most suitable cell strain 
based on the final yield of the protein. The following three expression systems were tested, BL21 
Star (DE3), BL21 star (DE3) pTf16, and Rosetta (DE3) pLysS. The protein yield was further 
optimized using BL21 Star (DE3) and BL21 Star (DE3) pTf16 using the following parameters for 
optimization (Table 2-4).  
Table 2-4. Overexpression optimization for co-expression construct. 
Cell strain IPTG concentration Temperature Duration of growth 
Post induction 
BL21 Star (DE3) 1 mM 37 ̊C 3 hrs 
BL21 Star (DE3) 0.15 mM 16 ̊C ON 
BL21 DE3 Star 
pTf16 
1 mM 37 ̊C 3 hrs 
BL21 DE3 Star 
pTf16 
0.15 mM 16 ̊C ON 
 
Optimized overexpression of the protein was done with BL21 Star (DE3) pTf16. Seed 
culture was grown using 10 mL LB broth. Seed culture (1:1000) was inoculated into 1 L of 2xYT 
media supplemented with ampicillin (100 μg/mL) and L-arabinose (0.5 mg/mL) in a 3 L Ultra 
yield Thomson flask. L-arabinose was added in the beginning to induce the expression of 
chaperone pTf16. The cells were induced at an OD600 value of 0.6 with 0.15 mM IPTG and grown 
at 16 C̊ overnight. Cells were harvested by spinning the cells in 1 L polycarbonate centrifuge 
bottles with a JLA 8.1 rotor at 5000 RPM (4 ̊C, 30 mins). Cell pellets from a total of 3 L culture 





2.7.1.1 Small scale purification 
0.5 g of frozen cell pellet (the equivalent of 50 mL culture) was resuspended in 1.5 mL 
(cell pellet to lysis buffer ratio, 1:3) of lysis buffer (LB 1) (50 mM Hepes pH 7.4, 200 mM NaCl, 
5% glycerol, protease inhibitor, lysozyme at 1 mg/ml). The resuspended lysate was incubated at 
37 ̊C for 30 minutes. The supernatant was recovered by spinning the lysate at 15000 RPM (TA 15-
1.5 rotor, Allegra 25R centrifuge) for 30 minutes using 2 mL microcentrifuge tubes. The 
supernatant was further incubated and nutated with 50 µL loose NiNTA resin for 1 hour at 4C. 
The resin was previously equilibrated with equilibration buffer 1 (EB 1) (50 mM Tris pH 7.5, 300 
mM NaCl, 20 mM Imidazole). Resins were washed with ~40 column volume (CV) of EB 1 to 
remove contaminants, and then the protein was eluted using 10 CV of elution buffer 1 (ELB 1) (50 
mM Tris pH 7.5, 300 mM NaCl, 250 mM Imidazole). The washes and elution fractions were 
collected by spinning the mix at 14000 RPM in a table-top centrifuge. 
2.7.1.2 Large scale purification 
 In order to yield more protein, the supernatant fractions from 8 small scale cultures (50 
mL) were combined and purified using a 1 mL HisTrap FF column. 40 CV of washes and 10 CV 
of protein elution were performed manually by passing EB 1 and ELB 1 respectively. A solubility 
screening of the pure protein was performed where 50 μL protein at 1 mg/mL was mixed with the 
final concentration of the following solvents. The solvents screened were 20% ethylene glycol, 
20% glycerol, 50% glycerol, 20% glycerol with 500 mM NaCl, and 20% PEG 4000. Dynamic 
Light Scattering (DLS) ((Wyatt DynaPro Plate Reader II) was used to screen the best storage buffer 
for the protein.  
2.7.2 HisGSK3β 
Cell pellets from 12 L culture (~90 g) were resuspended in ~300 mL of lysis buffer 2 (LB 
2) (50 mM Hepes pH 7.2, 5% glycerol, 50 mM NaCl, 1 mM phenyl-methyl-sulfonyl fluoride 
(PMSF)) at a pellet weight to lysis buffer volume ratio of 1:3. The resuspended cell pellet was 
lysed by cell disruption (Constant systems LTD 0.75KW, two runs with 25K Psi). The soluble 
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fraction of the lysate was collected after spinning at 40000 RPM for 45 minutes (Rotor type 70Ti, 
Beckman Coulter Optima XPN-100). 
Over the course of optimization for purification, we tried two protocols which differed 
based on the sequence of ion exchange and affinity chromatography.  
Protocol 1: Affinity -> Cation-exchange chromatography 
 The supernatant was loaded onto a 5mL His-Prep FF column equilibrated with 
equilibration buffer 2 (EB 2) (50 mM Tris pH 7.5, 300 mM NaCl, 12.5 mM imidazole). The 
column was washed with 40 CV of EB2 to remove contaminants. His-GSK3β was eluted with 10 
CV of elution buffer, ELB 1. A flow rate of 5 mL/min. was maintained throughout the affinity 
chromatography step. 
The affinity-purified protein was diluted with dilution buffer (DLB, 50 mM Hepes pH 7.2, 
5% glycerol, 50 mM NaCl) in a 1:7 volume ratio. The diluted pool was passed through a 1 mL SP 
sepharose column at a flow rate of 1 mL/min. The column was washed with 10 CV SP buffer A 
(SPA 1, 50 mM HEPES pH 7.2), and the proteins were eluted in a 20CV linear gradient from 0% 
to 100 % of SP Buffer B (SPB 1, 50 mM Hepes pH 7.2, 1 M NaCl). HisGSK3β containing fractions 
were pooled and treated with TEV protease at 1:10 molar ratio.  
The dialyzed and TEV-treated protein pool was purified using the same NiNTA column 
with similar method parameters. Cleaved GSK3β was collected from the flow-through and 
concentrated using a 3K MWCO 4 mL Amicon ultra-4 concentrator to a volume of 500 μL or not 
more than 1-2 mg/mL. The concentrated protein was loaded on to the size exclusion 
chromatography column, Superdex 200 increase 10/300 GL at 0.5 ml/min in gel filtration buffer 
(50 mM Hepes pH 7.2, 500 mM NaCl, 1 mM TCEP, 2 mM MgCl2). Gel filtration elution fractions 
were analyzed by SDS-gel electrophoresis to check for purity of the protein.  
Protocol 2: Cation-exchange -> affinity chromatography 
 The supernatant was diluted with 400 mL of DLB (in 1:7 ratio of pellet weight to DLB 
volume) to reduce the salt concentration for cation exchange. The diluted supernatant was applied 
to a 50 ml self-packed SP column equilibrated with 5 CV of SP Buffer A at a flow rate of 10 
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mL/min. The column was washed with 40 CV of SPA and elution was performed with a 10 CV 
linear gradient of SPB 1. 
The SP elution fractions containing His-GSK3β were pooled and applied to a 10 mL 
HisTrap FF column (two 5 mL HisTrap FF columns connected in tandem and equilibrated with 5 
CV with EB 2), and His-GSK3β was eluted with 10 CV of ELB 1.  
 TEV protease was added to the NiNTA elution pool in a molar ratio of 1:10. Tag cleavage 
and dialysis of the protein with dialysis buffer (DB, 50 mM Hepes pH 7.2, 500 mM NaCl, 5 mM 
BME, protein to buffer volume ratio of 1:100) were carried out simultaneously at room 
temperature for 17 hours. A clean and cleaved GSK3β pool was separated from the rest of the 
proteins in a flow-through fraction using the same 10 mL NiNTA column and purification 
protocol. Buffer exchange of GSK3β was done with the final buffer (50 mM Hepes pH 7.2, 500 
mM NaCl, 1 mM TCEP, 2 mM MgCl2). The pure crystallizable protein was further concentrated 
up to 4-8 mg/mL using a 3K MWCO 4 mL Amicon ultra-4 concentrator.  
2.7.3 HisGSK3β-StrnhD1 
2.7.3.1 Small scale purification test 
Small scale purification experiments for the co-expression construct were performed with 
0.5 g of cell pellet. Cells were lysed using lysis buffer 3 (LB 3, 50 mM Tris pH 7.5, 300 mM NaCl, 
5% glycerol, 20 mM imidazole, protease inhibitor tablet) at a pellet weight to buffer volume ratio 
of 1:3. The soluble fraction was collected by spinning the resuspension at 15000 RPM for 30 
minutes at 4 ̊C (TA 15-1.5 rotor, Allegra 25R centrifuge). The possible protein complex was eluted 
using 10 CV of ELB1 from 50 μL loose NiNTA resin that is equilibrated with 5 CV of EB 1. 
2.7.3.2 Large scale purification 
For the larger scale of purification, 2.5 g of cell pellets were resuspended in 7.5 mL of LB 
3 (ratio 1:3), and the supernatant was collected the same way as described for small-scale 
purification. A multiple step purification was performed for the larger batch.  
Protein was eluted with 10 resin volume of ELB 1 (50 mM Tris pH 7.5, 300 mM NaCl, 
250 mM Imidazole) from 500 μL loose NiNTA resin that is equilibrated by 10 resin volume EB 1 
(50 mM Tris pH 7.5, 300 mM NaCl, 20 mM Imidazole). 
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The His-GSK3 of the complex mixture was simultaneously dialyzed and cleaved with 
TEV protease in a 1:10 molar ratio in dialysis buffer (50 mM Hepes pH 7.2, 500 mM NaCl, 5 mM 
BME). The purification of the dialyzed protein/TEV mixture was performed the same way as 
described above, and the cleaved protein complex was recovered from the flow-through. Flow-
through protein was concentrated using an Amicon ultra 3K MWCO Ultra-4 mL concentrator. The 
concentrated protein sample was further purified with size exclusion chromatography with a 
Superdex 200 increase 10/300 GL (24 ml bed volume) column in gel filtration buffer (GF, 50 mM 
Hepes pH 7.2, 500 mM NaCl, 1 mM TCEP, 2 mM MgCl2) at a flow rate of 0.5 mL/min.  
2.8 Complex formation and biochemical analysis 
2.8.1 Complex formation with HisMBP-hD1 
Purified GSK3β and HisMBP-hD1 proteins were mixed at 200 nM concentration in 
Reaction buffer (RB 1) (50 mM Tris pH 7.5, 5 mM MgCl2, 0.01% Tween-20, 5 mM TCEP). The 
possible complex mixture was purified using 100 μL of loose NiNTA resin equilibrated with EB 
1 (50 mM Tris pH 7.5, 300 mM NaCl, 20 mM Imidazole). The resins were washed with 20 CV 
EB 1, and the complex was eluted with 10 CV of ELB 1 (50 mM Tris pH 7.5, 300 mM NaCl, 250 
mM Imidazole). A negative control experiment with just HisMBP- hD1 was included in the 
experiment as well. The complex formation was tested with western blot using antibodies for GSK 
and HisMBP- hD1. 
2.8.2 Complex formation with hD1 and FRATide 
Synthetic hD1 and GSK3β were mixed at 8 μM or 200 nM, at a 1:1 ratio. Running buffer 
(RB 2, 50 mM Tris pH 7.5, 5 mM MgCl2, 150 mM NaCl, 0.005% T-20, 1 mM TCEP) was used 
to mix both the proteins for complex formation. Protein mixture was incubated for 30 minutes in 
room temperature to help the complex formation process. The complex was further concentrated 
to ~50 μL or at least 7 mg/mL using a 3K MWCO 500 μL concentrator. 
Co-crystallization of hD1 and FRAtide with GSK3β was performed at 200 nM, at a 1:1:1 
ratio. The proteins were mixed in RB 2 and were concentrated up to ~8 mg/mL using a 3K MWCO 
500 μL concentrator.  
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2.9 Western blot 
Confirmation of protein identity for all constructs was done by western blot. Proteins of 
interest from the SDS gel were transferred to nitrocellulose membrane of pore size 0.45 μm. The 
transfer was done for 60 minutes at 350 mA. Two types of blocking solutions were used depending 
on the type of antibody: (i) Blocking solution 1 (BS 1, dry milk as the blocking agent) was made 
with 1xTBST (20 mM Tris-HCl of pH 7.4, 150 mM NaCl, 0.1% Tween 20) and 5% (w/v) dry milk 
powder and (ii) Blocking solution 2 (BS 2, Bovine serum albumin as the blocking agent) was made 
with 1xTBST and 5% (w/v) BSA powder. Blots were incubated with blocking solution for 1 hour, 
primary antibodies and conjugated antibodies for 1 hour, and secondary antibodies overnight.  
Complex confirmation in the interaction assay using HisMBP- hD1 and GSK3β was done 
with primary antibodies mouse anti-6xHis (to detect the His tagged protein) and mouse anti-
GSK3β (1-160) (for the detection of GSK3β). BS 1 was used to prepare the antibody solutions at 
the ratio of 1:2000 for the anti-His and 1:6000 for the anti-GSK antibody. Anti-mouse DyLight 
680 was used as the secondary antibody for this test, diluted with BS 1 at a ratio of 1:10,000. 
Fluorescent signals for the respective bands were recorded at 680 nm wavelength using G-box 
(Syngene). 
Expression confirmation for His-GSK3β from the co-expression construct (HisGSK3β-
StrnhD1) was done using mouse penta-His alexa flour 488 antibody. The antibody solution was 
prepared with BS 1 at a ratio of 1:10,000. The fluorescent signal at a wavelength of 488 nm was 
recorded using G-box. 
 Strep-tagged hD1 (Strn-hD1) of the co-expression construct was not visible in denaturing 
gels due to its low molecular weight. Expression of this protein was detected using StrepMAB-
classic mouse anti-strep antibody. BS 2 was used to dilute the antibody at a ratio of 1:2000. 
Chemiluminescence was used to detect signals in this case. The blots were incubated with the ECL 
solution (10 mM Tris pH 8.5, 0.19 mM p-Coumaric acid, 1.25 mM Luminol, 0.01% H2O2) for an 




2.10.1 Crystallization of protein complexes 
A sparse matrix commercial widescreen JCSG+ suite (MD1-40, Molecular dimensions) 
was used to screen potential crystallization conditions for the concentrated protein complex. The 
screening was done in a 96-2 well intelliplate (Art Robbins) using the Crystal Gryphon robot (Art 
Robbins). A 0.15 μl drop per well setting was used for the screen. The plates were stored inside 
the Crystal Farm imaging system. Promising conditions of crystallizations were further optimized 
with a fine screen to improve the quality of the crystals. Fine screen optimizations were done using 
a 24-well sitting drop Cryschem M plate (Hampton research: HR1-002). The freezing parameters 

















Table 2-5. Crystal freezing parameters. Harvest buffers used for each crystal conditions are 
described along with the buffer composition of the protein, interaction concentration, and 
crystallizing condition, etc. 
Complex type  Sample buffer Mother liquor (ML) 
(Crystallization) 
Harvest buffer (HB) 
(Freezing) 
GSK3β+ hD1 (8 μM) (Running buffer) 
50 mM Tris pH 7.5 
5 mM MgCl2 
150 mM NaCl 
0.005% Tween-20 
1 mM TCEP 
10 mM Hepes pH 7.5 
10%/14% PEG 8000 
8% Ethylene glycol 
10 mM Hepes pH 7.5 
14% PEG 8000 
10%/20%/30% 
Ethylene glycol 
GSK3β+ hD1 (8 μM) Running buffer 0.1 M Bicine pH 9 
10% PEG 6000 
0.1 M Bicine pH 9 
10% PEG 6000 
20% glycerol 
GSK3β+ hD1 (8 μM) Running buffer 0.1M Tris pH 8 
12% PEG 8000 
0.1 M Tris pH 8 
12% PEG 8000 
20% glycerol 
GSK3β+ hD1 (200 
nM) 
Running buffer 10 mM Hepes pH 7.5 
8%/10% PEG 8000 
8% Ethylene glycol 
10 mM Hepes pH 7.5 
14% PEG 8000 
20% ethylene glycol 
2.10.2 Diffraction studies 
Diffraction data for the frozen crystals were collected at 08ID-1 beamline (CMCF-ID) at the 
Canadian Light Source (CLS). The CMCF-ID beamline is equipped with a double crystal 













3 Chapter 3: Complex formation with HisMBP-hD1 and GSK3β  
3.1 Rationale 
The hD1 region of DISC1 protein is the most potent inhibitory fragment against GSK3β. 
Understanding the molecular framework involved in this inhibition is the primary objective of our 
project. The first strategy of yielding a hD1-GSK3β complex is to express and purify each protein 
independently. Complex formation was attempted by mixing the purified protein in equal molar 
concentration. In this strategy, the hD1 fragment was fused with a large tandem affinity tag that 
contains 6xHis and MBP. The 6xHis tag helps with targeted affinity purification, and the MBP tag 
increases the solubility of the small hD1 peptide.  
3.2 Overview 
This chapter describes the individual expression and purification protocols, including major 
optimizations for each interaction partners. Consistent overexpression of HisMBP-hD1 was 
achieved after selecting a clone with the highest expression level. Overexpression of GSK3β was 
optimized by other lab members. This chapter, however, discusses a few major challenges that I 
have overcome. By combining several chromatography steps in different sequences, highly pure 
GSK3 that is crystallizable was obtained. This chapter describes my attempt to obtain the binary 
complex by mixing together the purified HisMBP-hD1 and His-GSK3. 
3.3 Purification of HisMBP-hD1 
Expression levels of the protein were not clear when lysate samples were analyzed on a 
denaturing gel. Due to the lack of intense bands in lysate samples, small scale purification 
experiments were done to check the expression level. Purification of small-scale cultures (50 mL) 
after successful cloning revealed fluctuation in protein yield from one experiment to another. A 
clonal selection test was performed between four random colonies selected from the transformed 
plate. The small-scale purification resulted in a visible difference in the final protein yield (Fig 3-
1 (a)). The clone with the highest protein yield was selected for further use. A 1ml aliquot of an 
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overnight culture grown from this clone was frozen with 20% glycerol. Subsequent cultures were 
grown from this frozen stock to yield a consistently higher level of HisMBP-hD1. 
Maiden expression of the protein of interest required optimization of overexpression 
experiments. Overexpression experiments were done to evaluate and determine possible 
conditions to yield a very high amount of the protein. This test was done to compare several 
overexpression parameters, such as growth duration, temperature, and IPTG concentration. Small 
scale purification experiments were necessary for comparable protein yield so that the best 
expression condition could be determined. The conditions are listed below (same as Table 2-3), 
Flask (for both 
clones) 
IPTG concentration Temperature 
(̊C) 
Duration of growth 
Post induction 
1 1 mM 37 ̊C 3 hrs 
2 0.5 mM 25 ̊C ON 
3 0.2 mM 15 ̊C ON 
The overexpression optimization experiment of HisMBP-hD1 determined expression of 
the protein induced with 1 mM IPTG at 37 ̊ C for 3 hours to be the optimized set of conditions (Fig 
3-1 (b)). The protein elution fractions collected from 50 μL NiNTA resins contained a negligible 
level of contaminants and were pure enough for interaction experiments.  To complete the 
requirement of enough protein for interaction, a larger scale culture was purified (500 mL). 
Approximately 1 mg of protein with more than 80% purity was recovered from the larger-scale 
culture using 500 μL NiNTA resin (Fig 3-2). 
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Figure 3-1.  HisMBP-hD1 protein expression optimization. (a) A 10% SDS gel shows 
differential protein expression strength amongst 4 different clones. Samples are NiNTA elution 
from a small-scale purification. Clone 2 was selected and stored because of its higher expression 
level. (b) The denaturing SDS gel shows the test of varying over-expression parameters to achieve 
optimal protein yield. Elutions 1 and 2 represent protein eluted from the NiNTA resin.  
 
 
Figure 3-2. Large scale purification of HisMBP-hD1.  An SDS gel is showing a high yield of 
protein from 500 ml culture using the optimized O/E parameter(37 ̊C, 3 hours, 1mM IPTG), 
Soluble- a soluble fraction of the lysate (supernatant), FT- Flow-through, W1- Wash, E1 to E7- 




Purified protein was tested for size distribution and monodispersity using DLS. Molecular 
weight of the most common molecular species in the solution was 52 kDa (Table 3-1), which is 
very close to the theoretical molecular weight of HisMBP-hD1. To determine the optimal long-
term storage condition for HisMBP-hD1, DLS analysis were done with samples stored in different 
cryoprotectants. The solutions tested were 20% ethylene glycol, 20% glycerol, 50% glycerol, 20% 
glycerol with 500 mM NaCl, and 20% PEG 4000.  
Out of all the solvents tested, 20% ethylene glycol maintained the quality of the protein 
much better than others. DLS suggested the presence of a major molecular species with a molecular 
weight of ~77 kDa, which is also close to the theoretical molecular weight of HisMBP-hD1 (~48 
kDa). The protein species was also mostly monodispersed (Table 3-2). All HisMBP-hD1 pools 
were frozen with 20% ethylene glycol until GSK3β was purified for interaction and complex 
formation experiment.  
Table 3-1. DLS analysis of HisMBP-hD1. A dynamic light scattering analysis shows HisMBP-
hD1 maintains a monomeric state as a monodisperse (%Pd) species when expressed and purified 









% Mass % Number 
Peak 1 3.232 11.7 52 7.9 91.2 99.9 
Peak 2 14.066 11.7 1636 47.2 7.0 0.1 
Peak 3 69.443 11.0 68583 42.4 0.3 0.0 









Table 3-2. DLS analysis of HisMBP-hD1 with cryoprotectant. A dynamic light scattering 
analysis shows HisMBP-hD1 maintains a monomeric state and monodisperse (%Pd) species when 









% Mass % Number 
Peak 1 3.800 19.7 77 11.6 91.9 99.8 
Peak 2 22.473 44.8 4896 83.4 7.9 0.2 
Peak 3 261.880 38.9 1531280 5.0 0.3 0.0 
 
3.4 Purification of GSK3β 
Overexpression of GSK3β construct was optimized by Stephanie Saundh (Thesis titled, 
“Binding kinetics investigation of a peptide fragment of the psychiatric risk protein, DISC1, to the 
kinase GSK3β”. (2019)) and Anand Krishnan (Thesis titled, “Structural and functional 
characterization of the psychiatric risk protein, DISC1 and its interaction partner GSK3β). 
Overexpression of the protein was done using BL21 Star (DE3) pLysS, grown for 48 hours at 
18 ̊C, and induced with 0.15 mM IPTG at an OD600 value of 0.2.  
 According to the affinity -> cation-exchange chromatography protocol, HisGSK3β was 
collected from NiNTA resin as the major eluent in the first step. The elution fraction 2A2 (Fig 3-
3 (a)) contains significant contaminants such as ~75 kDa, ~60 kDa, and~25 kDa. The pooled 
protein fraction was then subjected to the cation exchange SP sepharose column, and HisGSK3β 
was eluted along with the contaminants between 29-77% salt gradient. The separation of 
contaminants from the protein of interest was inefficient (Fig 3-3 (b,c)). The separations of the ~60 
kDa, ~75 kDa, and ~25 kDa contaminants were inefficient even after the size exclusion 
chromatography step (Fig 3-3(d)). We tried the cation-exchange -> affinity chromatography 
protocol next (where the two chromatography steps were reversed) as the protein was impure for 

















Figure 3-3. Purification of GSK3β using NiNTA->Ion exchange method. (a) The NiNTA 
purification result shows the presence of GSK3β (~50 kDa) as a major band on the SDS gel. 
Presence of other contaminants (~75, 60, & 25 kDa) in higher amount can also be observed. FT- 
Flowthrough, W1/2/3- Washes, 2A2 to 2A7- Protein elutions. (b) & (c) Ion exchange 
chromatography results on the gel show almost no removal of any major contaminant from 
GSK3β. The pools of fractions between 29-77% gradient have GSK3β along with most of the 
major contaminants. (d) SDS denaturing gel shows the size exclusion chromatography results. The 
protein pool with GSK3β (~48 kDa) still showed the presence of the higher molecular weight 
contaminants (~60, ~75 kDa) and one lower molecular weight contaminant (~25 kDa).  
Using the new protocol, cell lysate was first subjected to cation chromatography under a 
low salt condition (50 mM). Most of the HisGSK3β protein was recovered from the column 
between 7-34% salt gradient. This step was able to separate some major lower molecular weight 
contaminants from HisGSK3β. The SP elution pool with the highest amount of GSK3β (3B1-4A1) 
(Fig 3-4 (a)) was loaded on a 10 mL NiNTA column. HisGSK3β was the major protein in the 
eluted fractions from this affinity chromatography step (1A1-1A5) (Fig 3-4(b)). 
The 6xHis tags were removed from GSK3β in the NiNTA elution pool using TEV protease. 
A complete and efficient cleavage was achieved after 16 hours of dialysis and cleavage. The 
TEV/GSK3 mixture was purified using the same 10 mL NiNTA purification protocol as before. 
Majority of the cleaved GSK3β protein was recovered with a low imidazole (12.5 mM) wash step 
(Fig 3-5(a), fractions 3B5-3C4). These fractions were pooled and concentrated up to 4 mg/mL 
using a 3K MWCO concentrator (Fig 3-5(b)). The resulting GSK3β was >90% pure, and it was 





      
 
Figure 3-4 Purification of GSK3β using ion exchange-> NiNTA method. (a) Ion exchange 
chromatography in the first step elutes most of the His-GSK3β between 7-35% of NaCl (3B1-4A1) 
(a gradient of 0 M to 1 M salt) 3A1-4B1- Ion exchange chromatography elutions (b) The SDS 
denaturing gel showed elution of His-GSK3β (1A1-1A5) with 250 mM imidazole when the ion 
exchange pool of His-GSK was applied to the NiNTA column. FT- Flowthrough, 1A1-1B3- 
Elutions 
 
                          
 
Figure 3-5. Final affinity purification and concentration of GSK3β. (a) A denaturing 12% SDS 
gel shows fractions with pure post cleavage GSK3β pool in the wash elution of NiNTA (with 12 
mM imidazole). 161-0363- Marker, 3B5-4A3- Washes, 5A3- Elution (b) The gel shows a sample 







3.5 Interaction of HisMBP-hD1 and GSK3β 
An in vitro complex formation assay was performed by mixing HisMBP-hD1 and GSK3β 
at a 1:1 ratio at 200 nM in the reaction buffer (RB 1, 50 mM Tris pH 7.5, 5 mM MgCl2, 0.01% 
Tween-20, 5 mM TCEP). The reaction mix was incubated with 100 μL of NiNTA resin 
equilibrated with EB 1 (50 mM Tris pH 7.5, 300 mM NaCl, 20 mM imidazole). The resins were 
washed with 20 CV EB 1, and the complex was eluted with 10 CV of ELB 1 (50 mM Tris pH 7.5, 
300 mM NaCl, 250 mM imidazole). The negative control experiment with just HisMBP-hD1 was 
mixed with the reaction buffer and purified in the same way. Detection of the binary complex 
formation was done by assessing whether the tagless GSK3β can be pulled down by NiNTA resin 
that binds to the 6xHis tagged HisMBP-hD1. The negative control contains the same mixture 
without the HisMBP-hD1 protein. Western blot was done to detect the presence of both proteins 
in different mixtures.  
GSK3β was detected in the wash and elution fractions in the NiNTA pull-down experiment 
(Fig 3-6). This result indicated possible interaction between both proteins, as GSK3 without His-
tag remained bound to His-MBP-hD1 when the latter was being eluted. Unfortunately, GSK3β 
was also detected in elution fractions of the negative control. This result was classified as a false 
positive result as GSK3β bound to the NiNTA resin non-specifically. 
 
Figure 3-6 Confirmation of interaction experiment. An Anti-His western blot compares NiNTA 
elutions of the negative control (only GSK3β) and test (HisMBP-hD1 and GSK3β interaction). 
The presence of GSK3β in the elutions of the negative control is an indication of a false-positive 





3.6.1 Improved purification results due to change in chromatography sequence 
The gel filtration results of the protein pool recovered from NiNTA -> cation exchange 
protocol show elution of GSK3β with two major higher and lower molecular weight contaminants 
(~75 kDa and ~25 kDa). Presence of a contaminant in comparable quantity to the protein of interest 
is not suitable for interaction or crystallization experiments. The second affinity chromatography 
step in cation exchange -> NiNTA protocol, however, was able to generate pure crystallizable 
GSK3β. The advantage of cation-exchange -> NiNTA process over the NiNTA -> cation exchange 
sequence could be due to concentration-dependent interaction between the major contaminant 
proteins and GSK3β.  
It is possible that the interaction between these two proteins is much stronger and maybe 
irreversible at high concentrations such as NiNTA elution in the first step. Affinity 
chromatography of cell lysate concentrates the protein elution at the first step. This interaction 
could be hard to disrupt in the subsequent steps when NiNTA elution fractions are treated with 
1mL SP column. In order to deal with this possible problem, we also tried diluting the NiNTA 
elution fraction before loading them on to the SP cation exchange column. The results were not 
positive as there was a significant loss in GSK3β when it was diluted in a comparatively purer 
state. Cation exchange -> NiNTA protocol was in an attempt to counteract this problem where the 
cell lysate was diluted before being loaded on to the SP column in the first step.  
The cell lysate was diluted up to 7 times before it was passed through a 50 mL cation 
exchange column in the first step. The diluted state of supernatant (10X) maintained a lower 
density of contaminants and GSK3β around each other, leading to the weak interaction between 
the 25 kDa contaminant and GSK3β. It may have helped in an efficient separation of the lower 
molecular contaminant and protein of interest using this protocol.  
3.6.2 False-positive interaction result could be due to GSK3β 
The interaction experiment between GSK3β and HisMBP-hD1 had false-positive results. 
It failed as GSK3β bound to NiNTA resin despite having no 6xHis tags. If the experiment had 
worked, there would have been no signal recorded from elution fractions of the negative control. 
The suspicion that GSK3β could be the reason for the false-positive test came to light after we 
took a detailed and closer look at the purification results of the kinase.  
55 
 
In the cation exchange -> NiNTA purification protocol, GSK3β was eluted in the wash 
fractions (Fig 3-5(a)) of the second NiNTA chromatography after the 6xHis tags were cleaved. 
Without any histidine tag, GSK3β should ideally be eluted in the flow-through fraction. Elution of 
the protein in wash fraction suggests GSK3β binds non-specifically to the NiNTA resin. Increasing 
the imidazole concentration for washing and equilibration can eliminate non-specific binding and 
could help in obtaining a more conclusive result from the interaction experiment.  
3.6.3 The low salt condition may disfavour a physiological interaction 
The reaction buffer (RB 1, 50 mM Tris pH 7.5, 5 mM MgCl2, 0.01% Tween-20, 5 mM 
TCEP) used for the interaction process had a meager amount of salt. Synthetic hD1 is more soluble 
in the low salt buffer. It is also possible that the low salt buffer could hamper the solubility of 
bigger proteins like HisMBP-hD1 and GSK3β in the reaction solution. A decrease in solubility 
could have caused partial or complete precipitation of the proteins on the NiNTA resin. This 
hypothesis could be tested by using a reaction buffer with a higher salt content (e.g., 300-500 mM) 
for the interaction experiment that could promote better solubilization of the proteins94.  
3.6.4 Size-exclusion chromatography as an alternative method to test the 
interaction 
Size-exclusion chromatography is often used to monitor the particle size of different 
protein solutions. This method could also be utilized to facilitate the detection of a possible 
physiological complex. The interacting proteins would form a molecular species of higher mass 
and size upon the achievement of a stable complex. GSK3β (~47 kDa) and HisMBP-hD1 (~49 
kDa) would elute under their specific peaks when loaded individually. Upon forming a complex, 
they would create a species of average molecular weight around 96 kDa. The binary protein 
complex molecule of larger size would elute under a different peak that correlates to its size. This 
shift in the molecular weight could be used as a tool to detect complex formation. Deciding the 
nature of the interaction could become a challenge if the interaction leads to a heterogenous 









4 Chapter 4: HisGSK3β-StrnhD1 (co-expression construct) 
4.1 Rationale  
Co-expression of interacting proteins is one method to yield physiological protein 
complexes. A T7-promoter-based poly-cistronic vector was used to express GSK3β and hD1 in 
the same vector. The rationale of co-expression strategy relies on the availability of a cellular 
milieu for better interaction between both proteins of interest. If their interaction in vivo requires 
simultaneous expression or folding, this method may be deemed helpful for complex formation. 
As described in the method section, the presence of different tags in different proteins provides 
modularity for downstream affinity purification processes. In case they form a stable complex, 
affinity purification of one protein should ideally result in the co-elution of the other.  
4.2 Overview 
The current chapter discusses the results derived from co-expression strategy. As the co-
expression strategy was attempted for the first time, overexpression and purification experiments 
needed optimization for optimal yield of the proteins. The overexpression of the protein was 
quantified across multiple bacterial strains and overexpression parameters. Purification tests were 
performed along with respective western blots to confirm each protein. The crystallization trial of 
the purified GSK-StrnhD1 is also covered in this chapter.  
4.3 Purification of the HisGSK3β-StrnhD1 construct 
Protein expression levels needed to be tested for the novel HisGSK3β-StrnhD1 construct. 
This co-expression construct contained both the interacting proteins with their respective N-
terminal affinity tags. Overexpression tests were done with three cell strains: BL21 Star (DE3), 
BL21 Star (DE3) pTf16, and Rosetta 2 (DE3) pLysS. BL21 Star (DE3) pTf16 is an expression 
system with a pTf16 plasmid. This plasmid codes for pTf16 chaperone which could help in better 
folding and expression of our proteins of interest95. Protein expression levels were compared 
between pre- and post-induction samples from cultures of all three systems. All cultures in this 
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experiment were grown under the same conditions. A protein band correlating to the molecular 
weight of HisGSK3β (~47 kDa) was visible in the post-induction sample (lysate) on the denaturing 
gel. This optimization test revealed a visibly higher expression level of GSK3β in BL21 Star (DE3) 
and BL21 Star (DE3) pTf16 systems (Fig 4-1(a)).  
 Overexpression of the HisGSK3-StrnhD1 construct was done for the first time, hence 
confirmation of individual protein expression was necessary. As the band correlating to the 
HisGSK3β molecular weight had a visibly higher band density, and western blot with mouse anti-
Penta His Alexa 488 confirmed the identity. The test showed that the overexpressed protein was, 
in fact, HisGSK3β (Fig 4-1(b)). 
            
 
Figure 4-1. Overexpression confirmation of HisGSK3β from co-expression construct. (a) A 
12% denaturing gel depicts a comparison of His-GSK3β (~49 kDa) expression between pre- and 
post-induction samples from 3 different cell strains. A putative GSK3β band is visible in the post-
induction lanes of BL21 DE3 (*) and BL21 DE3 (*) pTf16 cell strains. GSK bands are highlighted 
with rectangular boxes. An overexpression in 2xYT media for 3 hours at 37 ̊ C using 1 mM IPTG 
was followed for all cell strains. (b) The western blot with anti-PentaHis confirms His-GSK3β in 







Expression confirmation of HisGSK3β from the HisGSK-StrnhD1 construct was done with 
two systems, BL21 Star (DE3) and BL21 Star (DE3) pTf16. This preliminary test was done at 
37ºC where expression was induced at 1 mM IPTG for 3 hours. More optimization tests were 
necessary to explore higher expression levels under different conditions. Lower temperature 
(16ºC) induction and growth over a more extended period (overnight) were tested for both the 
expression systems. A much higher protein expression level was observed in BL21 Star (DE3) 
pTf16 system. The optimized overexpression parameter is as follows, induction with 0.15 mM 
IPTG at 16ºC and total growth duration of overnight (Fig 4-2).  
 
Figure 4-2. Overexpression optimization of the co-expression construct. Overexpression 
parameters were optimized (Conditions A/B/C/D) for the BL21 DE3 (*) and BL21 DE3 (*) pTf16 
cell strain. A very high level of His-GSK3β (~49 kDa) expression was observed in BL21 DE3 (*) 
pTf16 cell strain when protein expression was induced with 0.15 mM IPTG at 16 ̊ C, and it was 
grown for overnight. Most of the expressed protein was also present in the soluble fraction. Sup-
supernatant. Pre and Post- Pre and post-induction samples, Sup- Soluble supernatant fraction, 




A longer period of growth can lead to a change in the pH of the culture media, and a 
destabilized pH can potentially hamper proper expression and folding of proteins. Therefore, a 
final optimization test was done to compare the final yield of protein from 2xYT media and a pH-
controlled TB media. No significant difference was observed when proteins were eluted from a 
small-scale purification (0.5g cell weight) using 50 µL NiNTA resin (Fig 4-3(a)). This experiment 
showed the successful purification of the HisGSK3β from HisGSK-StrnhD1 co-expression 
construct. 
           
 
Figure 4-3. Small scale purification and detection of the possible complex. (a) A denaturing 
gel shows similar levels of overexpression between 2xYT and TB media (Lane marked with E(1:1) 
under both 2xYT and TB media. A small-scale purification using NiNTA (50μL) method yields 
HisGSK3β as the main protein in the elution. Some endogenous chaperones and proteins are also 
present along with GSK. (S- Supernatant, FT- Flowthrough, W1/2/3- Washes, E1- Elution) 
Volume written beside the labels is the amount of denatured protein loaded on the gel. (b) A 
western blot with anti-strep antibody detects the presence of StrnhD1 in the elution fraction as well 
as supernatant, flow-through and wash from NiNTA step. Presence of Strep signal provides strong 
evidence for complex formation. StrnhD1 not involved in the interaction is seen in sup/FT/wash. 
Dual Xtra standard/M- protein marker, Sup-Supernatant, FT- Flowthrough, W1/2/3- Washes, 






 The goal of co-expression construct was to express both proteins in the same system, 
possibly yielding a physiological complex. Both proteins were cloned with different tags for 
different affinity purifications. If they form a stable complex, then purifying one protein should 
ideally elute the other. His-GSK3β had a distinctive thick band in the denaturing gel of Fig 4-3 (a). 
However, the peptide Strn-hD1 band was not distinctively visible in the elution fractions of the 
small-scale purification results (Fig 4-3(a)). Hence, western blot using anti-strep antibody was 
used to detect the peptide and the putative complex. Signal for Strn-hD1 peptide (~6.8 kDa) was 
observed at ~12 kDa molecular weight range in the elution fractions containing HisGSK3β (Fig 4-
3(b)). Presence of the peptide along with HisGSK3β strongly suggested the presence of a binary 
protein complex. 
 Crystallization trials require a pure and concentrated protein sample. A larger-scale 
purification (2.5 g cell) was done to yield enough protein sample for the crystallization experiment. 
Because of the higher expression level, HisGSK3β was tracked through subsequent purification 
experiments. Approximately 300 µg of HisGSK3β was recovered using 500 µL loose NiNTA 
resin. The elution fractions, however, contained equal proportions of endogenous contaminant 
proteins (~60 kDa, & ~75 kDa) (Fig 4-4(a)). The histidine tag was removed from GSK3β using 
TEV protease, and cleaved protein was again purified using NiNTA affinity chromatography. The 
cleaved protein remained bound to the contaminants and was recovered from the flow-through 






                 
 
Figure 4-4. Affinity purification and His-tag cleavage. (a) NiNTA purification of a 2.5 g cell 
batch from the co-expression construct provides an elution fraction on a denaturing 12% SDS gel 
with HisGSK3β as one of the major proteins. Other significant bands present could be chaperone 
pTf16 (~56 kDa) and an endogenous chaperone (~75 kDa). M- Marker, Sup- supernatant, FT- 
Flow-through, W1/2/LW1/LW2- Washes, E1-E5- Elution fractions. (b) 6xHis tag cleavage using 
TEV protease was able to achieve a very efficient cleavage of GSK3β as seen from the SDS gel. 
A comparison of pre-cut and post-cut sample showcases lower band size of GSK3β (~47 kDa) 
compared to HisGSK3β (~49 kDa). Most of the cleaved protein was collected from flow-through 
and wash fractions as expected. Major contaminant bands, however, were still eluted with GSK, 
requiring a size exclusion chromatography. Pre-cut- Sample before adding TEV protease, Post-
cut- Sample was taken when cleavage was complete. FT- Flow through.  
Size exclusion chromatography efficiently separates proteins based on the difference in 
their molecular weight. A maximum resolution of the proteins is achieved when the load volume 
is between 0.5-2% of the total column volume. A maximum sample size of 500 µL is required for 
the Superdex 200 15/300GL column with 24 mL bed volume. The concentration step of the TEV 
treated GSK3β-StrnhD1 sample before the size exclusion step revealed a gradual loss of GSK3β 
(Fig 4-5(a)). Protein samples from different stages of the concentration steps were tested to 
determine an optimal concentration value. Running these samples on a denaturing gel revealed a 
significant loss of GSK3β once the concentration value crossed 1.35 mg/mL. A maximum 
concentration of 1.3 mg/mL was targeted for gel filtration load sample in further experiments (Fig 
4-5(b), (c)). The possible binary protein complex was eluted in the void fraction of the repeated 
gel filtration experiment. A possible higher-order oligomerization or aggregation was suspected 
because of this result. A significant loss of contaminants was observed in the void volume fraction 




the presence of contaminants that were not visible in the diluted pool. The void volume protein 
was concentrated up to 6 mg/mL (Fig 4-5(d)). 









                
 
Figure 4-5. Size exclusion chromatography of His-tag cleaved GSK3β. (a) A denaturing gel 
shows bands of concentrated TEV cleaved GSK3β pool at 3 mg/mL. GSK3β is displayed inside a 
rectangular box. The ratio of the contaminants to GSK3β is alarmingly high compared to pre-
concentrated fractions. (b) A concentration test reveals loss of GSK3β from the cleaved protein 
pool when the concentration reaches more than ~2 mg/mL. A sample concentrated to ~1.5 mg/mL 
was loaded on a size exclusion chromatography column. (c) Fractions from size exclusion 
chromatography revealed the GSK3β elution in the void volume (A7-A11) of the gel filtration 
column Superdex 200 15/300GL. Other larger contaminants were eluted at later fraction sizes 
correspondent to their molecular sizes. (d) GSK3β sample collected from the void fraction and 
concentrated to 6 mg/mL at ~70% purity. (e) A chromatogram shows three main peaks of the gel 
filtration chromatogram, where the first prominent peak represents elution of the complex, and 









4.4 Biochemical characterization and Crystallization 
DLS and crystallization trials were performed with the GSK3β-StrnhD1 sample purified as 
described above. The theoretical molecular weight of the binary protein complex would be ~55 
kDa (assuming the interaction is 1:1). Still, it eluted in the void volume of the size exclusion 
chromatography step (molecular weight of the complex being more than 440 kDa, according to 
the manual). DLS sheds light on an approximate molecular size of the most common molecular 
species present in a protein solution, so we decided to use DLS before using the sample for a 
widescreen crystallization trial. The most common species in the solution had a molecular weight 
of 483 kDa (Table 4-1). A high molecular weight could be due to a nonameric complex formation 
or aggregation due to the presence of other contaminants with the complex.  









% Mass % Number 
Peak 1 8.353 11.3 483 3.8 66.7 99.0 
Peak 2 36.229 35.6 14965 96.2 33.3 1.0 
 
The purified GSK3β-StrnhD1 was subjected to crystallization using the commercially 
available sparse matrix JCSG+ screen. The development of dense precipitate like possible 
crystalline structures, was observed in the A9 condition, which contains 0.2M ammonium chloride, 
20% w/v PEG 3350 as the mother liquor (Fig 4-6). This strategy was not further pursued as the 
strategies described in the next chapter gave us more promising results. 
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Figure 4-6. Crystallization of co-expression complex. (a) JCSG+ sparse matrix widescreen was 
used to find a crystallizing condition for the co-expression complex. Picture shown is for condition 
A9 from day 1. (b) The same well from day 3 can be seen to have developed many densely 


















4.5.1 Dimer-like behavior of the Strn-hD1 peptide in SDS gel 
The anti-strep blot in Fig 4-3(b) was performed to identify strnhD1 as a part of the 
physiological complex with GSK3β. The signal for Strep-tag was, however, detected at ~12 kDa, 
which is twice the theoretical molecular weight of Strn-hD1 (~6.8 kDa). This signal suggested a 
SDS-stable dimerization of the peptide. The hD1 peptide sequence had never been reported to 
dimerize under denaturing conditions. Thus, this finding requires literature and experimental 
research to determine the actual cause.   
A study published by Walkenhorst (2009) on decreased electrophoretic mobility of small 
peptides in SDS-PAGE suggests a specific interaction between Asparagine (Asn) and SDS 
detergent micelles as a driving factor. The slower movement of the peptide could be the reason for 
the misleading dimerization results96. The protein sequence of StrnhD1 also contains an asparagine 
residue at the 19th position as part of the TEV cleavage site. The polar asparagine residue may lead 
to dimerization-like results when present with detergents like SDS. 
If Asn19 on StrnhD1 was responsible for the slower electrophoretic mobility and cause the 
StrnhD1 to migrate like a dimer on the SDS gel, then TEV cleavage of the peptide, removing 
Asn19,  should lead to an SDS band that reflects the molecular weight of a monomeric StrnhD1. 
Since the western blot results were done with the samples from the first affinity chromatography 
test before it was treated with TEV protease. A future blot with a TEV-treated protein sample could 
support this hypothesis. 
4.5.2 Improvement of the purification protocol 
An essential prerequisite of the crystallization process is the purity of the protein. While a 
high quantity of the possible protein complex has been achieved, we only managed to get a final 
purity of ~70%. A combination of many chromatography techniques could be applied to improve 
the purity level of the final yield in future experiments.  
Talon resin (CoNTA) could be used instead of NiNTA resin in the first step for more 
specific binding. Talon resin uses Cobalt ion (Co2+) instead of Nickel ion (Ni2+) as the immobilized 
metal ion. Talon resin has also shown a more specific binding of poly-histidine tags under milder  
elution conditions. This could potentially separate some of the contaminants in the first step97. 
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The GSK3β-StrnhD1 protein complex elutes in the void volume fraction of Superdex 200 
increase 10/300 GL column. Resolution of the protein separation for this column lies between 10 
kDa to 500 kDa. One of the general causes for elution of proteins in the void volume fraction is 
either higher oligomerization or aggregation of the protein. The higher oligomerization in this case 
seems unlikely as the upper limit of resolution is ~10 times the theoretical molecular weight of the 
complex (~55 kDa). This hypothesis is based on the assumption that the stoichiometry of GSK3β 
and hD1 interaction is 1:1. A solubility screening experiment using DLS could determine the 
proper buffer environment to prevent aggregation of the complex. An oligomeric and properly 
folded complex would possibly elute in gel filtration fraction corresponding to its size. 
However, the protein size and molecular weight estimation from size exclusion 
chromatography is usually based on the assumption that the protein is globular in nature. But, if 
the GSK3β-StrnhD1 complex adapts an elongated fibrous shape instead of globular shape, it would 
elute in the void volume fraction. The size estimate from the size exclusion chromatography will 
not be accurate despite the molecular weight of the protein complex being within the fractionation 
limit of the column. Indeed, preliminary negative-stained EM images of GSK3/hD1 (discussed 
in the next chapter) suggests the complex may be fibrous and elongated in shape.  
4.5.3 Crystallization hit requires further optimization 
The crystallization screening using JCSG+ sparse matrix gave a preliminary hit. Most of 
the structures were clusters of spherulites with a rounded morphology. It is necessary to try a vast 
range of parameters to improve the quality of the crystals. A fine screen optimization of the protein 
complex is essential. In future trials, the PEG percentage and type can be used as variables over a 
wider range. Individual spherulites were found with 20% PEG 3350.  So a range of 10-30% of 
PEG 3350 could be a start. In addition, the concentration and the type of monovalent salt could be 











5 Chapter 5: GSK/hD1Peptide 
5.1 Rationale 
Crystallization of a protein complex relies on its purity, quantity, and interaction parameters. 
Our lab has investigated the biophysical and the biochemical nature of the interaction between 
GSK3β and a synthetic hD1 peptide. So, my priority shifted to obtaining co-crystals of 
GSK3β/hD1 using conditions we learned from the in vitro assays.  
5.2 Overview 
This chapter describes the co-crystallization methods used for GSK3β, hD1, and FRATide. 
Crystallization of GSK3β was tested first to check the quality and purity of the protein. The GSK3β 
crystals were soaked in various concentrations of hD1 to yield a binary complex crystal but soaking 
caused damage to the crystals. The failed soaking experiment led us to try co-crystallization of 
GSK3β and hD1 after they interacted in vitro. Optimization of sample preparation to ensure protein 
complex formation was done before co-crystallization. 
5.3 Crystallization of GSK3β with synthetic hD1 
The successful purification of GSK3β in high purity and quantity was followed by the 
crystallization of the protein. Based on the published conditions by Aoki et al. (2000), purified 
GSK3 at 6 mg/mL was crystallized using the sitting drop method98. Multiple thin square like 
crystals of GSK3β with a size ~ 0.3 x 0.5 mm were observed in the condition containing 0.1 M 
Tris pH 8, 20% PEG 8000 (Fig 5-1). Crystals were harvested and tested for diffraction at the home 
source X-ray diffractometer. These diffracting crystals were soaked for 5 minutes in 2.5 μM hD1 
solution made with the harvest buffer (10 mM Hepes pH 7.5, 14% PEG 8000, 10% ethylene 
glycol). The diffraction spots from the hD1-soaked GSK3β crystals was streaky (Fig 5-2(c), Fig 
5-3), suggesting damage to the crystal. The streaky pattern often arises due to structural defects in 




Figure 5-1. GSK3β crystals. GSK3β crystals seen through a polarizer lens in a sitting drop plate. 
Crystallizing condition was 0.1 M Tris pH 8, 20% PEG 8000. The square plate-like crystals grew 
mostly in 2 dimensions leaving the crystals very thin. Most of the crystals were singular and 
diffracted well. 
GSK3β from the same batch was simultaneously used for the interaction and co-crystallization 
experiments. GSK3β protein and hD1 peptide were mixed to interact at 8 μM concentration, at a 
molar ratio of 1:1. The lyophilized powder of synthetic hD1 peptide was dissolved in the buffer 
with no monovalent salt (50 mM Tris pH 7.5, 5 mM MgCl2, 0.005% T-20, 1 mM TCEP) to make 
a 500 µM stock solution. Then, the peptide stock was diluted with an equal volume of the high salt 
buffer (50 mM Tris pH 7.5, 5 mM MgCl2, 300 mM NaCl, 0.005% T-20, 1 mM TCEP), resulting 
in a working stock solution of the peptide with 150 mM NaCl in the buffer, which is the same as 
the buffer for the interaction assay. 8 µM of the working peptide solution was mixed with GSK3β 
in the same buffer and allowed to incubate for 30 minutes at room temperature. This interaction 
condition was based on the published SPR protocol (Thesis by Saundh, Stephanie. Binding kinetics 
investigation of a peptide fragment of the psychiatric risk protein, DISC1, to the kinase GSK3β 
(2019)). The binary protein complex was concentrated up to 8.7 mg/mL. The complex was 
subjected to crystallization using the sparse matrix JCSG+ screen.  
At least three conditions from the widescreen test provided promising crystallizing conditions 
for the possible protein complex. These three conditions were used as a reference for a fine screen 
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matrix used to fine-tune the quality of crystals (Fig 5-2(a), (b), (c)). Three major conditions with 
good crystal hits were observed within a week. The list of conditions is mentioned in Table 5-1 
following the crystal figures. 





Figure 5-2. GSK-hD1 crystals. Set of GSK-hD1 crystals achieved using fine screening, based on 
three separate hits from JCSG+ (B4, E10, E12). The following table contains the details of 






A series of freezing/diffraction test revealed that 20% ethylene glycol was the optimal 
cryoprotectant for these crystals. The co-crystals (Fig 5-2) were harvested and cryoprotected in the 
presence of 2.5 μM hD1 and incubated for 5 minutes before freezing. The diffraction spots were  
observed at 2.8 Å resolution, at CMCF-ID beamline of CLS, USask. However, the spots were 
streaked, indicating that the harvesting procedure needed further optimization. 
Table 5-1. Crystallizing conditions for GSK-hD1 crystal hits. The table lists the 
crystallization conditions and quality of crystals depicted in Figure 5-2 
Figures Crystallization condition Approximate size and shape 
(for the one used for 
diffraction) 
5-2 (a) 0.1 M Hepes pH 7.5 
8% Ethylene glycol 
8% PEG 8000 
0.1 mm x 0.05 mm 
A group of the square plate-
like thin crystals as well as 
many tiny joint crystals 
5-2 (b) 0.1 M Hepes pH 7.5 
8% Ethylene glycol 
10% PEG 8000 
0.1 mm x 0.05 mm 
Most of the crystals were tiny 
and clustered, very few of 
them were single 
5-2 (c) 0.1 M Bicine pH 9 
10% PEG 6000 
0.2 mm x 0.1 mm X 0.5 mm 
One big crystal with an 






Figure 5-3. Diffraction data collected from crystals of Fig 5-2(c). The diffraction pattern shown 
in the picture was streaky, suggesting crystal damage due to extra peptide soaking, and the data 
was not of sufficient quality to solve the structure. 
 To avoid crystal damage, we attempted to harvest the co-crystals without soaking 
with additional peptide, from which a better data set was obtained. Diffraction data from the new 
batch of co-crystals were recorded up to 2.23 Å. Molecular replacement was successfully 
performed. Two GSK3β molecules are present in each a.s.u., but no density for the hD1 peptide 
was observed (Fig 5-4).  
 
Figure 5-4. Crystals of GSK3β-hD1 at 8 μM. Single and square plate-like crystals with an 




Table 5-2. Structural data analysis for the crystal from Fig 5-4. Values in the brackets are for 
the highest resolution shell (2.30-2.23 Å).  
Observed parameters Values 
Wavelength (Å) 0.97949 
Space group P1 
Unit cell (Å) and angles 63.75, 67.27, 67.40, 78.1, 76.8, 89.4 
All reflections 170448 
Unique reflections 49770 
Multiplicity 3.4 
Resolution (Å)  46-2.23 
Completeness * 95.6% (81%) 
Multiplicity # 3.4 (3.1) 
I/Sigma (I) 6.9 (0.3) 
CC1/2 0.994 
Rmerge $ 0.116 (3.195) 
*  The completeness represents the percentage of reflections recorded compared to theoretically 
possible measurements. # Multiplicity shows the quantity of redundant measurements. $ Rmerge 
stands for internal R factor. 
A careful review of GSK3β structure article published by Dajani et al. (2001) suggested 
that GSK3β forms a dimer at micromolar concentration. Since we prepared our previous complex 
by mixing GSK3 and hD1 at 8 µM concentration, we reasoned that GSK3 would exist as a 
dimer before the addition of hD1. If the binding surface of hD1 is at the GSK3 dimer interface, 
then a GSK3/hD1 would not be possible in the condition that we used for complex formation; 
therefore, we repeated sample preparation by mixing the proteins at a concentration of 200 nM 
and repeated crystallization screen with the widescreen sparse matrix JCSG+. Indeed, we 
discovered multiple new hits with the new sample. In contrast to only observing crystals with 
square, plate-like morphologies, we obtained crystals with diamond and needle shapes in different 
conditions. This change strongly suggested a possible structural change at the molecular level. 
Crystals obtained from the fine screen based on the widescreen hits are listed in the following 
figure (Fig 5-5(a), (b), (c)).  
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Figure 5-5. GSK-hD1 crystals at 200 nM. Crystals obtained from GSK3β-hD1 interaction 
experiment done at 200 nM. Arrows in fig (c) point towards crystalline needle structures. The 







Table 5-3. Crystallization conditions for crystals obtained from the interaction at 200 nM. 
Figures Crystallization condition Approximate size and shape 
(for the one used for 
diffraction) 
5-5 (a) 0.1 M Hepes pH 7.5 
8% Ethylene glycol 
8% PEG 8000 
0.03 mm x 0.03 mm 
A group of the small square 
plate-like thick and joined 
crystals as  
5-5 (b) 0.1 M Hepes pH 7.5 
8% Ethylene glycol 
10% PEG 8000 
0.5 mm x 0.5 mm 
One big square plate like 
crystal 
5-5 (c) 0.1 M Bicine pH 9 
8% PEG 6000 
Multiple needle flowers, size 
less than 0.05 mm 
 
Structural data were obtained from crystals of Fig 5-5 (b) and (c). The data statistics for 











Table 5-4. Structural data statistics of crystals from Fig 5-5(b). Values in the brackets are for 
the highest resolution shell (3.08-2.90 Å). 
*  The completeness represents the percentage of reflections recorded compared to theoretically 
possible measurements. # Multiplicity shows the quantity of redundant measurements. $ Rmerge 










Observed parameters Values 
Wavelength ( Å ) 0.97949 
Space group P121 
Unit cell ( Å ) and angles 67.41, 113.48, 67.51, 90.0, 102.63, 90.0 
All reflections 100914 
Unique reflections 22003 
Multiplicity # 4.6 (4.7) 
Resolution ( Å )  113.59-2.90 
Completeness * 99.9% (100%) 
I/Sigma (I) 9.53 (1.26) 
CC1/2 0.95 
Rmerge $ 0.119 (0.424) 
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Table 5-5. Structural data statistics of crystals from Fig 5-5(c). Values in the brackets are for 
the highest resolution shell (3.08-2.90 Å). 
*  The completeness represents the percentage of reflections recorded compared to theoretically 
possible measurements. # Multiplicity shows the quantity of redundant measurements. $ Rmerge 
stands for internal R factor. 
5.4 Crystallization of GSK3β with synthetic hD1 and FRATide 
The hypothesis of my project predicts that the binding of FRATide to the GSK3β disrupts 
the binding of the GSK3β inhibiting region of hD1 GI to the kinase. We tried to crystallize the 
GSK3β with hD1 peptide using multiple strategies. However, to prove the hypothesis I suggested, 
a FRATide and hD1 bound GSK3β crystal structure is necessary. The comparison of structural 
framework changes between GSK3β-hD1 and GSK3β-hD1-FRATide crystals is required to prove 
the hypothesis.  
To examine the effect of FRATide binding, an interaction and co-crystallization experiment 
was performed. FRATide, hD1, and GSK3β were mixed at 200 nM in reaction buffer (50 mM Tris 
pH 7.5, 5 mM MgCl2, 150 mM NaCl, 0.005% T-20, 1 mM TCEP) and allowed to interact for 30 
minutes. The interaction pool was concentrated up to 7.8 mg/mL and subjected to the sparse matrix 
widescreen, JCSG+ screen. Fine screens based on preliminary hits were performed. Needle-shaped 
crystals were obtained using a 1:1 mixture of the protein complex and mother liquor (0.1 M bis-
Observed parameters Values 
Wavelength ( Å ) 0.97949 
Space group P1 21 1 
Unit cell ( Å ) and angles 106.78, 85.64, 116.50, 90.00, 95.3, 90.00 
All reflections 113827 
Unique reflections 35500 
Multiplicity # 3.2 (3.3) 
Resolution ( Å ) 116.07-3.15 
Completeness * 99.9% (100%) 
I/Sigma (I) 1.5 (0.1) 
CC1/2 0.972 
Rmerge $ 0.244 (4.485) 
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tris pH 5.5, 0.3 M magnesium formate, based on the H1 condition of JCSG+). Crystals were 
harvested and frozen with the mother liquor and 20% ethylene glycol as the cryoprotectant. 
Structural data will be collected from these crystals once the synchrotron reopens. 
 
Figure 5-6. Crystals of GSK3β-hD1-FRATide. Crystalline needles are observed in the 
crystallization drop of GSK3β co-crystallized with hD1 and FRATide peptides at 200 nM. 
Crystallizing condition- 0.1 M Bis-Tris pH 5.5, 0.3 M magnesium formate 
5.5 Discussion 
Three strategies were used to generate the GSK3β-hD1 complex. The strategy described in 
this chapter was able to provide the most promising results. The crystallization screens often 
require optimization and availability of the protein complexes in higher quantities. We were able 
to express ~600 μg of GSK3β from a 12 L batch cell culture using our optimized overexpression 
and purification protocol. The current yield of GSK3β provides a sufficient amount to generate 
complexes to set up one to two 96-wide screen conditions only. In the future, we could explore 
using a fermenter to increase the size of the bacterial culture or using a eukaryotic expression 
system, such as yeast or insect cell lines that may provide a higher protein yield. Nonetheless, we 
are able to routinely obtain crystallizable GSK3 with our current expression and purification 
protocol. 
Our first attempt to freeze co-crystals of GSK3/hD1 with additional soaking of hD1 was 
unsuccessful. Crystals were soaked for 5 minutes in 5 μM peptide solution made with 
cryoprotectant harvest buffer. Diffraction spots observed for this batch were streaky. Streaky spots 
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arise when crystal packing is disrupted. Comparison of the first and second co-crystallization trials 
revealed that soaking the crystals with an excess of peptides may have caused distortion to the 
crystal lattices, thus affecting the integrity99. The detrimental effect is not surprising since hD1 is 
quite a large molecule for soaking experiments.  
Although we are hopeful that the new crystals with different morphologies grown from 
new crystallization conditions contain the peptide(s) bound to GSK3, we will not know until we 
determine the crystal structures. The possibility that the new crystallization conditions disrupt the 
complex remains and we may end up with GSK3 alone in these new crystal forms. Crosslinking 
the complex is a possible solution if we failed to find a crystallization condition where the 
peptide(s) remain bound to GSK3. Chemical crosslinking molecules such as glutaraldehyde can 
be used to stabilize the protein complexes. Polymerization of glutaraldehyde and its interaction 
with lysine residues of the protein of interest helps preserve the structure of the enzymes. We could 
use chemical crosslinking reagents to covalently link hD1 to GSK3. This method will ensure that 
we do not waste time pursuing conditions that favour the crystallization of GSK3 alone. To make 
sure the peptide and the kinase remain bound, it may also be beneficial to introduce a flexible 
glycine rich linker in the construct. Linkers often promote the proximity of the interaction partners 
without interefering with the protein-protein interaction framework.  
Alternative to crystallography, electron microscopy may provide structural information of 
GSK3/hD1. I have performed negative staining of the GSK3/hD1 and GSK3/hD1/FRATide 
complexes in their orginal buffers. We were able to identify some recurrent shapes of the protein 
particles. In addition, we can utilize this method to screen for buffers that disrupt and stabilize the 
complex to complement our crystallization effort.  
Finally, hD1 is a small region of the 100 kDa full-length DISC1 protein. The structure of 
GSK3/hD1 will partially reflect how the full-length proteins interact. Extending the length of the 
peptide to various lengths (possibly targeting for a nearby predicted α-helix sequence) in the co-
expression complex could generate additional interacting regions that may stabilize the complex 
more. Ultimately, we may need to understand how the full-length proteins interact to understand 
the complete inhibition mechanism of DISC1 against GSK3β. Crystallization of such a large 
complex is a challenging task and only provides a static image of the complex. Biochemical and 






6 Conclusion and future work  
The primary objective of my thesis was to yield crystals of GSK3β, hD1, and FRATide. I 
used three distinct strategies to develop the crystals of the binary/ternary protein complex. The 
objective was achieved as we derived crystals for the complexes under different crystallization 
conditions. However, we need to solve the crystallographic data collected to determine the atomic 
structure of the complex. Future work in extension of this thesis will focus on solving the data.  
Three strategies were attempted to obtain crystallizable samples. Strategy 1 resulted in a 
false positive interaction result between GSK3β and HisMBP-hD1, which will require a thorough 
investigation. This strategy was preliminary, and we never reached up to the crystallization step. 
This approach will not have high priority in the future due to the extensive experiments needed.  
In the future, I would like to further explore strategies 2 and 3. Strategy 2 was based on the 
co-expression of the interacting protein partners in a single protein expression system. Expression 
systems with GSK3β alone were inefficient as it has been predicted that the expression of the 
kinase may not be favourable for the growth of bacterial cells. The cells cope with the negative 
effect by limiting the expression of the kinase. The expression of GSK3β using strategy 2, 
however, resulted in very high yield (~10 times) compared to HisGSK3β expression using strategy 
1. The high yield may have been possible due to the expression of the kinase inhibiting peptide 
hD1 in the same system. This could be a firm indication of intracellular interaction. We observed 
the growth of many clusters in the crystallization drop. Optimization of the purification protocol 
for strategy 2 would be worth the resources to yield enough protein for multiple crystallization 
trials. 
We derived crystals from strategy 3, but the data needs to be analyzed. Using the 
suggestions mentioned in the discussion section of chapter 5, we could fast-track the development 
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